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Across the globe, numerous kid-ney transplant candidates and donors are linking up in often 
complicated ways to facilitate more 
transplants through exchange pro-
grams, or swaps. The largest swap so 
far, which was orchestrated by the 
National Kidney Registry (NKR) 
and involved 60 lives and 30 kid-
neys, was described recently in 




r=2). Also, in early February the 
NKR announced that it had facilitated 
its 400th exchange transplant. These ef-
forts by the NKR and other programs 
could not come at a better time. Nearly 
90,000 people in the United States are 
waiting for a kidney transplant, and 
many will die before a suitable organ 
becomes available. The shortage is ex-
pected to worsen.
Such living donor chains and simpler 
closed-loop paired exchanges, which in-
volve two pairs of donors and recipients, 
assume that kidneys from living donors 
are of comparable quality and antici-
pated longevity. But how true is this 
assumption? Potential recipients often 
wonder, will the kidney received from a 
stranger—particularly an older one—be 
as good as a kidney donated by a loved 
one?
“In a proposed kidney paired dona-
tion match, if an old donor–recipient 
pair is matched to a young donor–re-
cipient pair, the young recipient may 
feel disadvantaged and may not be will-
Antiplatelet Therapy in Patients with Chronic 
Kidney Disease: Is It Safe? 
Recent study results should encourage more donor 
paired exchanges
Antiplatelet therapy that inhibits blood clotting can be life-saving for individuals at high risk for 
cardiovascular disease or stroke. At first 
glance, this should apply to patients 
with chronic kidney disease (CKD), 
who are more likely to die of cardiovas-
cular disease than of any other cause. 
But nonatherosclerotic conditions 
such as cardiac failure, sudden cardiac 
death, and arrhythmia are more com-
mon causes of cardiovascular events in 
individuals with CKD than in the gen-
eral population, and the bleeding risk 
of antiplatelet agents may be greater 
among people with CKD because of 
impaired hemostasis.
Investigators recently published a re-
view in the Annals of Internal Medicine 
on the benefits and harms of antiplate-
let agents in these patients, focusing on 
cardiovascular events, mortality, and 
bleeding. 
“Until now, data from studies done 
in the general population were extrap-
olated to people with chronic kidney 
disease,” said senior author Giovanni 
Strippoli, MD, PhD, who holds titles 
at the school of public health at the 
University of Sydney in Australia, the 
Mario Negri Sud Consortium in Italy, 
Does Living Donor Age Matter in Kidney 
Transplantation?
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ing to trade with an older donor,” said 
Paolo Ferrari, MD, director of Austral-
ia’s national registry for paired kidney 
exchanges. “Refusal to participate in an 
exchange could break the chain of po-
tential matches identified after a match 
run and could limit the success of a kid-
ney paired donation program.”
A recent study by John Gill, MD, 
and his colleagues, of the University of 
British Columbia, in Vancouver, Cana-
da, that appears in the Clinical Journal 
of the American Society of Nephrology 
investigates this issue. The researchers 
analyzed the survival of kidneys from 
donors of different age groups that were 
transplanted into recipients of different 
age groups. Their study included data 
from all adult kidney transplants from 
living donors that were performed in the 
United States from January 1988 to De-
cember 2003, with follow-up through 
September 2007.
Age	not	an	issue
The investigators found that except for 
recipients aged 18 to 39, who benefited 
the most when they received kidneys 
from donors aged 18 to 39, donor age 
between 18 and 64 had a minimal effect 
on the survival of transplanted kidneys. 
Specifically, the researchers noted a dif-
ference of only 1 to 2 years in allograft 
half-life, with no graded association, 
among different donor age groups. 
“These findings show that in contrast 
to deceased donor transplantation, the 
age of a living donor has little impact 
on transplant survival,” Gill said. “This 
information should help increase par-
ticipation and efficiency of living donor 
paired exchange programs because it al-
leviates patient concerns about receiving 
a kidney from an older aged living do-
Living Donor Age
Continued from page 1
nor that currently limits acceptance of a 
proposed transplant in paired exchange 
programs.” 
More experience is needed to deter-
mine the outcome of transplants from 
living donors aged 65 and older relative 
to younger living donors, Gill said.
In addition to expanding participa-
tion in exchange programs by blood 
group and tissue-incompatible donor–
recipient pairs, the results may also en-
courage participation of more compat-
ible donor–recipient pairs. Finally, the 
information should prompt exchange 
programs to reexamine any matching 
algorithms that emphasize donor–re-
cipient age matching.
“This study’s observation supports 
data from the Australian registry, where 
13.8 percent of live donors were aged 
60 years or older, showing that live do-
nor–recipient age difference does not 
impact graft or patient survival,” said 
Ferrari, who was not involved with the 
study by Gill and his associates. Those 
findings were published by Ferrari and 
his colleagues in 2011 in Nephrology 
Dialysis Transplantation. 
“Taken together, these findings of 
the two registry data are of major rel-
evance for policy and decision mak-
ing in kidney paired donation,” Fer-
rari said. They reinforce the view that 
it is acceptable to ignore donor–donor 
or donor–recipient age differences as 
a scoring parameter in ranking match 
combinations.”
Weighing	options
Gill and his team also juxtaposed 
their results against the probabilities 
that wait-listed patients would receive 
a kidney from a deceased donor and 
their risk of being excluded from trans-
plantation during the study because of 
death or permanent removal from the 
wait-list.
The probability of deceased donor 
transplantation after 3 years of wait-
listing ranged from 21 percent to 66 
percent depending on patients’ blood 
type and antibody levels, whereas the 
probability of being excluded from 
transplantation ranged from 6 percent 
to 27 percent by age, race, and type of 
kidney disease. Gill noted that when 
patients consider these probabilities, 
many will likely find that participating 
in living donor paired exchanges—and 
possibly receiving a kidney from an 
older donor—is a better option than 
continuing to wait for a deceased donor 
transplant.
Yet the study included relatively few 
living donors aged 60 and older, the 
authors said, noting that there may be 
certain patient subgroups who tolerate 
dialysis relatively well, so that waiting 
while they continue to receive dialysis 
would be a reasonable consideration. 
Also, they were unable to evaluate the 
effect of other important donor factors 
that may affect transplant survival and 
confound the results, including predo-
nation kidney function, donor blood 
pressure, and diabetes in the donor.
The authors stressed that their find-
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Transplant Care Since 1967 
The Kidney and Pancreas Transplantation Program at 
Montefiore Medical Center in New York City has performed 
more than 3,000 adult and pediatric kidney transplants, and 
has a three-year patient survival rate greater than 90 percent.  
The Children’s Hospital at Montefiore offers a dedicated nephrology 
and transplant program and is ranked among America’s top pediatric 
hospitals by U.S. News & World Report. Our pioneering work includes:
•	Desensitization for high immunologic risk 
patients as well as access to donor chain 
registries and donor swaps
•	Single-port donor nephrectomy offered for 
selected donor candidates 
•	State-of-the-art outpatient and  
inpatient facilities
•	A dedicated live donor evaluation team with 
a concierge level of services for living donors 
•	Customized postoperative care plans with 
our referring physicians, ensuring regular 
contact with the patient is maintained. 
To refer a patient, please call 877-CURE-KDNY (877-287-3536).
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Kidneys are the most commonly transplanted organ, and now with the advent of transplant chains that use several sets 
of matched pairs, the numbers of these logistically challenging 
operations are poised to rise to levels unanticipated only a few 
years ago. At the same time, increased scrutiny of chain trans-
plants, which rely on living donors, is emerging from all corners 
of the industry.
A recent conference of national and regional kidney transplant 
partners represented a first attempt to agree on the direction of 
their field. Insurers and representatives from several registries and 
the large federally run United Network for Organ Sharing (UNOS) 
also attended. UNOS manages the national transplant waiting list 
and maintains the database that has all organ transplant data, 
from every transplant that happens in the United States.
Held in late March in Herndon, VA, the Consensus Conference 
on Kidney Paired Donation had an ambitious goal—to seek con-
sensus among the 70 participants on ways to increase the vol-
ume of transplants that involve kidney paired donation (KPD). The 
genesis of the conference was the idea that KPD is the most 
effective approach to recruit a substantial pool of high-quality kid-
neys from healthy living donors. These donors would not have 
volunteered otherwise because their kidneys weren’t a compat-
ible match for their family member or loved one. Despite the need 
and opportunities for this type of donation, KPD remains an often 
unused option.
An announcement from the University of California, San Francis-
co—where the conference’s lead organizer Sandy Feng, MD, PhD, 
is a transplant surgeon—described the first consensus meeting 
and noted that “the emergence of multiple KPD programs with 
diverse approaches and processes attests to a lack of consensus 
as to how to maximize the benefit and minimize the risk of KPD.”
While the participants expressed a desire for a unified registry 
that would provide a centralized system for storing and accessing 
data about donors and recipients, they ultimately could not agree 
over how this unifying effort would take place, according to Kevin 
Sack, who reported on the conference for The New York Times.
One mathematician from the U.S. Naval Academy, Sommer 
Gentry, who had been working on donation models, wanted to 
eliminate barriers to a national registry. “With two pools of 100, 
you get fewer opportunities than with one pool of 200,” to match 
donors to recipients.
Sack noted that Feng was concerned that unifying all of the cur-
rent registries into one system might stifle the innovations used 
by successful registries like the National Kidney Registry. “Maybe 
we can have different operations with common allocation meth-
ods and principles, [without complete unification of systems],” 
Feng said. 
ings should not be interpreted as a dismiss-
al of the importance of living donor age 
on transplant outcomes. Most recipient 
age groups with living donors between 40 
and 64 had a small but statistically signifi-
cant increased risk of allograft loss com-
pared with those whose living donors were 
18 to 39 years old, and in all recipient age 
groups, the greatest donor age-associated 
risk of allograft loss was among recipients 
from living donors aged 65 and older. This 
increased risk of allograft failure with older 
donor age is consistent with results from 
a recent single-center American Journal 
of Transplantation publication from the 
Mayo Clinic that showed an association 
between living donor age and the risk of 
death-censored graft loss. That study  did 
not show an association between living 
donor age and patient death. 
Although questions still remain about 
the comparable quality of different do-
nors’ organs, the results shown by Gill and 
his team provide valuable information to 
transplant candidates and potential do-
nors who are weighing their options. 
Study co-authors include Peter Chang, 
MD, Jagbir Gill, MD, James Dong, 
Caren Rose, Howard Yan, MD, David 
Landsberg, MD (University of British Co-
lumbia, in Vancouver, Canada); and Ed-
ward Cole, MD (University of Toronto, in 
Canada).
Disclosures: The authors reported no fi-
nancial disclosures.
The article “Living donor age and kid-
ney allograft half-life: implications for 
living donor paired exchange programs,” 
appeared online at http://cjasn.asnjour-
nals.org/ in March 2012, doi: 10.2215/ 
CJN.09990911. 
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and Diaverum in Sweden. “Previous re-
search from our group and others has 
shown that such extrapolations could be 
very dangerous, and interventions that 
may be very good in the general pop-
ulation may have no effect or even be 
harmful in people with chronic kidney 
disease 
Paying particular attention to pa-
tients with CKD while conducting clin-
ical trials will only become more impor-
tant. Approximately 10 percent to 15 
percent of the adult population world-
wide have the disease, and its prevalence 
is on the rise because of increasing rates 
of diabetes and obesity.
Analyzing	available	data
Mining Embase and Cochrane databas-
es from 1980 through November 2011 
without language restriction, Strippoli 
and his colleagues selected randomized 
trials that included adults with CKD 
and compared antiplatelet agents with 
standard care, placebo, or no treatment. 
“Nephrology is lagging behind all 
other disciplines of internal medicine 
when it comes to randomized trials, 
and a strong effort is needed to do more 
trials and to summarize existing knowl-
edge from the few small existing trials 
that have been published,” said Strippo-
li. Many of the trials in the analysis were 
not performed to study issues specifical-
ly in kidney disease but included a small 
portion of people with the condition.
Nine trials (9969 participants) pro-
vided information on antiplatelet treat-
ment among persons with CKD who 
had acute coronary syndrome or were 
undergoing coronary artery interven-
tion and were considered at high risk 
for subsequent vessel closure. All data 
for these trials were post hoc analyses 
for subgroups of participants with CKD 
from larger trials. The trials provided 
data for glycoprotein IIb/IIIa inhibitors 
(abciximab, eptifibatide, or tirofiban) 
or clopidogrel (two trials, 4498 partici-
pants), and all involved coadministra-
tion of aspirin with or without heparin. 
The median follow-up time was 12 
months.
 Another 31 trials provided data 
on 11,701 persons with stable or no 
cardiovascular disease who received an-
tiplatelet therapy. Twelve trials studied 
antiplatelet effects on mortality, pro-
gression of kidney disease, or safety in 
patients who had glomerulonephritis, 
diabetic nephropathy, or an impaired 
GFR regardless of cause. The agents 
administered included aspirin, dipyri-
damole, aspirin and dipyridamole, or a 
thienopyridine (clopidogrel or ticlopi-
dine), and the median follow-up time 
was 12 months. Seventeen of the trials 
provided shorter-term data (median of 
6 months of follow-up) for a variety of 
antiplatelet treatments in persons who 
were receiving or would soon require 
dialysis. Four trials administered an-




In general, the investigators found that 
the available information on antiplatelet 
therapy in patients with CKD is of low or 
very low quality, with considerable vari-
ation in trial duration, heterogeneity in 
the definitions and assessment of bleed-
ing outcomes, reliance on subgroup data 
from major trials, and substantial meth-
odologic limitations in data for patients 
with stable cardiovascular disease.
The researchers reported low-quality 
evidence that in people with acute coro-
nary syndromes, glycoprotein IIb/IIIa 
inhibitors or clopidogrel plus standard 
care had little or no effect compared with 
standard care alone on all-cause or car-
diovascular mortality or on myocardial 
infarction, but the treatments increased 
serious bleeding by up to 40 percent. 
Also according to generally low-quality 
evidence, antiplatelet therapy prevented 
myocardial infarction (lowering the risk 
by about 34 percent) but caused uncer-
tain effects on mortality and increased 
minor bleeding by approximately 70 per-
cent compared with placebo or no treat-
ment in persons with stable or no cardio-
vascular disease.
These findings indicate that any bene-
fits of antiplatelet therapy for people with 
CKD are uncertain and are potentially 
outweighed by bleeding hazards. 
“All in all, these drugs should be used 
with care and attention, as all doctors do, 
and we should always think before we 
prescribe,” said Strippoli. Also, he and 
his coauthors noted that many patients 
would not be likely to accept the risk for 
major bleeding to reduce their risk for 
myocardial infarction without proven 
reductions in death or the need for coro-
nary revascularization.
“This systematic review and meta-
analyses primarily highlight the rather 
limited evidence from existing rand-
omized trials about the efficacy and safe-
ty of antiplatelet agents for preventing 
cardiovascular events and death across 
the spectrum of chronic kidney disease 
and in those receiving dialysis or a renal 
transplant,” said Alan Go, MD, who is 
the director of the comprehensive clini-
cal research unit and the regional medical 
director for clinical trials at Kaiser Perma-
nente Northern California and who was 
not involved with the research.
Given the low quality of the avail-
able evidence, the investigators advocate 
for specific trials evaluating antiplatelet 
therapies, including newer agents, in in-
dividuals with CKD and coexisting acute 
or stable cardiovascular disease. They also 
note that no data are currently available 
on antiplatelet use in dialysis patients or 
kidney transplant recipients who have 
acute coronary syndromes or require cor-
onary artery revascularization. 
“Given the risks of bleeding associated 
with these agents, additional studies are 
needed to delineate the net clinical ben-
efit or harm at different levels of renal 
function through randomized trials as 
well as studies done in large, diverse clini-
cal practice populations that are more 
representative,” said Go. 
Antiplatelet Therapy 
Continued from page 3
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ASN Cosponsors Congressional Briefing on Racial 
Disparities in Kidney Disease
Kidney disease affects millions in the United States across all populations, but it is more 
common among minorities. African 
Americans, Hispanics, Pacific Island-
ers, and Native Americans face a dis-
proportionately increased risk for de-
veloping kidney disease.  
Broadening knowledge about the 
disparities in kidney care that mi-
norities confront is essential to re-
solving those disparities. On April 
19, 2012, the American Society of 
Nephrology (ASN), Dialysis Patient 
Citizens (DPC), and the National 
Urban League led a congressional 
briefing on kidney health disparities. 
Maria Cristina Arce, MD, and Neil 
R. Powe, MD, addressed members 
of Congress and Capitol Hill staff-
ers about this critical issue on ASN’s 
behalf. 
A nephrology fellow at Stanford 
University School of Medicine, Arce 
presented information on kidney 
disease in the Hispanic population. 
She noted that Hispanic ethnicity 
is associated with an increased risk 
for end stage renal disease (ESRD) 
compared with whites—an increase 
not explained by higher prevalence 
of diabetes or by diabetes severity. In 
addition, a higher number of younger 
Hispanics are starting dialysis, possi-
bly due to worsening rates of obes-
ity, earlier onset of diabetes and hy-
pertension, and faster progression of 
kidney disease.  Hispanics are 15 per-
cent less likely to use arteriovenous 
access for their first hemodialysis ses-
sion, Arce said.
Powe spoke to the audience at 
the congressional briefing about the 
many factors that contribute to a 
rate of kidney failure in minorities 
that is up to four times greater than 
in whites. Chief of Medicine at San 
Francisco General Hospital and Vice-
Chair of Medicine at the University 
of California San Francisco, Powe 
noted that kidney disease occurs 
more often in minorities and starts 
earlier. Socioeconomic status, life-
style and quality of care explain 44 
percent of the threefold excess risk of 
chronic kidney disease (CKD) in Af-
rican Americans compared to whites. 
African Americans are also much 
less likely to get transplants or to be 
placed on the transplant waiting list, 
said Powe. His presentation echoed 
Arce’s findings that minorities in the 
United States are referred to nephrol-
ogists much later than whites.  
Powe emphasized to lawmakers 
the current and future opportunities 
for the federal government to ad-
dress racial and ethnic disparities in 
kidney care. These include compara-
tive effectiveness studies of treatment 
in minorities, enhanced patient and 
provider education, and increasing 
support for demonstration projects to 
assess the effectiveness of changes in 
health care.
DPC board member Eric Edwards 
spoke to those assembled about liv-
ing with kidney disease. Also present-
ing at the briefing were Kafui Agbe-
menu, Health Advocate for the Urban 
League, who spoke about how the 
Urban League in Pittsburgh is im-
proving minority access to health 
care. Dana Atwater of Baxter Health-
care presented general information 
on CKD in the United States.
The American Society of Neph-
rology supports a variety of efforts 
to address and resolve disparities in 
kidney care in the United States and 
worldwide, including support of Sen-
ate bill 2163 that promotes research 
regarding disparities and access to 
care. ASN encourages members to 
contact your members of Congress 
to support this bill at http://capwiz.
com/asn/home. 
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administered erythropoiesis-stimulating agents (ESAs) to target a 
hemoglobin level of greater than 11 g/dL.
•  No trial has identified a hemoglobin target level, ESA dose, or 
dosing strategy that does not increase these risks [see Warnings 
and Precautions].
•  Use the lowest OMONTYS dose sufficient to reduce the need for red 
blood cell (RBC) transfusions [see Warnings and Precautions].
INDICATIONS AND USAGE
Anemia Due to Chronic Kidney Disease
OMONTYS is indicated for the treatment of anemia due to chronic kidney disease 
(CKD) in adult patients on dialysis.
Limitations of Use
OMONTYS is not indicated and is not recommended for use:
• In patients with CKD not on dialysis because of safety concerns in this 
population [see Warnings and Precautions].
• In patients receiving treatment for cancer and whose anemia is not due to 
CKD, because ESAs have shown harm in some settings and the benefit-risk 
factors for OMONTYS in this setting have not been evaluated [see Warnings 
and Precautions].
• As a substitute for RBC transfusions in patients who require immediate 
correction of anemia.
• OMONTYS has not been shown to improve symptoms, physical functioning 
or health-related quality of life.
CONTRAINDICATIONS
OMONTYS is contraindicated in patients with:
• Uncontrolled hypertension [see Warnings and Precautions].
WARNINGS AND PRECAUTIONS
Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism
• In controlled clinical trials of other ESAs in patients with CKD comparing 
higher hemoglobin targets (13 – 14 g/dL) to lower targets (9 - 11.3 g/dL)
(see Table 2), increased risk of death, myocardial infarction, stroke, 
congestive heart failure, thrombosis of hemodialysis vascular access, and 
other thromboembolic events was observed in the higher target groups.
• Using ESAs to target a hemoglobin level of greater than 11 g/dL 
increases the risk of serious adverse cardiovascular reactions and has 
not been shown to provide additional benefit. Use caution in patients with 
coexistent cardiovascular disease and stroke. Patients with CKD and an 
insufficient hemoglobin response to ESA therapy may be at even greater 
risk for cardiovascular reactions and mortality than other patients. A rate 
of hemoglobin rise of greater than 1 g/dL over 2 weeks may contribute to 
these risks.
• In controlled clinical trials of ESAs in patients with cancer, increased risk for 
death and serious adverse cardiovascular reactions was observed. These 
adverse reactions included myocardial infarction and stroke.
• In controlled clinical trials, ESAs increased the risk of death in patients 
undergoing coronary artery bypass graft surgery (CABG) and deep venous 
thrombosis (DVT) was observed in patients undergoing orthopedic procedures.
The design and overall results of 3 large trials comparing higher and lower 
hemoglobin targets are shown in Table 2 (Normal Hematocrit Study (NHS), 
Correction of Hemoglobin Outcomes in Renal Insufficiency (CHOIR) and Trial 
to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT)).
Table 2  Adverse Cardiovascular Outcomes in Randomized Controlled Trials 







Time Period of Trial 1993 to 1996 2003 to 2006 2004 to 2009
Population
Patients with CKD 
on hemodialysis 
with coexisting CHF 
or CAD, hematocrit
30 ± 3% on
epoetin alfa
Patients with CKD 







CKD not on 
dialysis with 




Higher vs. Lower 
(g/dL)










12.5 (12.0, 12.8) 
vs.
10.6 (9.9, 11.3)
Primary Endpoint All-cause mortalityor non-fatal MI
All-cause mortality, 
MI, hospitalization





Hazard Ratio or 
Relative Risk
(95% CI)
1.28 (1.06 – 1.56) 1.34 (1.03 – 1.74) 1.05 (0.94 – 1.17)
Adverse Outcome for 
Higher Target Group All-cause mortality All-cause mortality Stroke
Hazard Ratio or 
Relative Risk 
(95% CI)
1.27 (1.04 – 1.54) 1.48 (0.97 – 2.27) 1.92 (1.38 – 2.68)
Patients with Chronic Kidney Disease Not on Dialysis
OMONTYS is not indicated and is not recommended for the treatment of anemia 
in patients with CKD who are not on dialysis.
A higher percentage of patients (22%) who received OMONTYS experienced a 
composite cardiovascular safety endpoint event compared to 17% who received 
darbepoetin alfa in two randomized, active-controlled, open-label, multi-center 
trials of 983 patients with anemia due to CKD who were not on dialysis. The trials 
had a pre-specified, prospective analysis of a composite safety endpoint consisting 
of death, myocardial infarction, stroke, or serious adverse events of congestive 
heart failure, unstable angina or arrhythmia (hazard ratio 1.32, 95% CI: 0.97, 1.81).
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence 
in Patients with Cancer receiving ESAs
OMONTYS is not indicated and is not recommended for reduction of RBC 
transfusions in patients receiving treatment for cancer and whose anemia is not 
due to CKD because ESAs have shown harm in some settings and the benefit-risk 
factors for OMONTYS in this setting have not been evaluated.
The safety and efficacy of OMONTYS have not been established for use in patients 
with anemia due to cancer chemotherapy. Results from clinical trials of ESAs 
in patients with anemia due to cancer therapy showed decreased locoregional 
control, progression-free survival and/or decreased overall survival. The findings 
were observed in clinical trials of other ESAs administered to patients with: breast 
cancer receiving chemotherapy, advanced head and neck cancer receiving radiation 
therapy,  lymphoid malignancy, cervical cancer, non-small cell lung cancer, and 
with various malignancies who were not receiving chemotherapy or radiotherapy.
Hypertension
OMONTYS is contraindicated in patients with uncontrolled hypertension.
Appropriately control hypertension prior to initiation of and during treatment with 
OMONTYS. Reduce or withhold OMONTYS if blood pressure becomes difficult to 
control. Advise patients of the importance of compliance with antihypertensive 
therapy and dietary restrictions.
Lack or Loss of Response to OMONTYS
For lack or loss of hemoglobin response to OMONTYS, initiate a search for 
causative factors (e.g., iron deficiency, infection, inflammation, bleeding). If 
typical causes of lack or loss of hemoglobin response are excluded, evaluate 
the patient for the presence of antibodies to peginesatide. In the absence of 
antibodies to peginesatide, follow dosing recommendations for management 
of patients with an insufficient hemoglobin response to OMONTYS therapy.
Contact Affymax, Inc. (1-855-466-6689) to perform assays for binding and 
neutralizing antibodies.
Dialysis Management
Patients may require adjustments in their dialysis prescriptions after initiation of 
OMONTYS. Patients receiving OMONTYS may require increased anticoagulation 
with heparin to prevent clotting of the extracorporeal circuit during hemodialysis.
Laboratory Monitoring
Evaluate transferrin saturation and serum ferritin prior to and during OMONTYS 
treatment. Administer supplemental iron therapy when serum ferritin is less 
than 100 mcg/L or when serum transferrin saturation is less than 20%. The 
majority of patients with CKD will require supplemental iron during the course 
7" x 10" 
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Twelve quality measures aimed at improving care for patients with kidney disease were re-
cently endorsed by the National Qual-
ity Forum (NQF). The metrics cover 
several areas of renal care, including 
anemia, dialysis adequacy, and vascular 
access. “These measures will help ensure 
renal patients receive safe, high-quality, 
and compassionate care throughout the 
course of treatment,” said the president 
and CEO of NQF, Janet Corrigan, 
PhD, MBA.
Thirty-three possible measures for 
renal care were evaluated and then nar-
rowed to the 12 endorsed by the NQF 
board of directors. Three new meas-
ures—for anemia and cardiovascular 
disease in patients with kidney dis-
ease—were added to the nine metrics 
previously endorsed by NQF.
The NQF renal quality measures 
pertain to aspects of care for patients 
with chronic kidney disease, end stage 
renal disease, and those undergoing di-
alysis. They include the serum phospho-
rus concentration in dialysis patients, 
metrics targeted at reducing the use of 
catheters and increasing the use of ar-
teriovenous fistulas in vascular access 
for hemodialysis, and a risk-adjusted 
standardized mortality ratio for dialysis 
facilities. 
Created to improve health care quali-
ty, the NQF works to find consensus on 
national goals for performance improve-
ment, endorses standards for measuring 
performance, and promotes these goals 
through education and outreach. The 
NQF kidney disease criteria were de-
termined in collaboration with several 
stakeholders including the Centers for 
Medicare & Medicaid Services, Kidney 
Care Quality Alliance, and the Ameri-
can Medical Association Physician Con-
sortium for Performance Improvement
Members of the kidney community 
have until May 1, 2012, to appeal any 
of the 12 endorsed quality measures 
before final approval by NQF. 
Kidney	Disease	and	Minorities	in	the	United	States
• Minorities are more likely to receive a late evaluation by a nephrologist
• Minorities in the United States with CKD are more likely to have uncontrolled blood pressure
• African Americans with kidney disease are 3.6 times more likely to progress to kidney failure than 
whites, and six times more likely to develop kidney failure related to hypertension
• Hispanics and Native Americans are approximately two times more likely to progress to kidney failure 
than whites
• African Americans are more likely to receive hemodialysis, and less likely to receive peritoneal dialysis 
and a transplant
• African Americans are less likely to be waitlisted for and receive a kidney transplant
• Research, education, and clinical care focused on prevention can help eliminate disparities in kidney 
disease
of ESA therapy. Following initiation of therapy and after each dose adjustment, 
monitor hemoglobin every 2 weeks until the hemoglobin is stable and sufficient 
to minimize the need for RBC transfusion. Thereafter, hemoglobin should be 
monitored at least monthly provided hemoglobin levels remain stable.
ADVERSE REACTIONS
The following serious adverse reactions observed during clinical trials with 
OMONTYS are discussed in greater detail in other sections of the labeling:
• Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism 
[see Warnings and Precautions]
• Hypertension [see Warnings and Precautions]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse 
reaction rates observed in the clinical studies of OMONTYS cannot be directly 
compared to rates in the clinical trials of other drugs and may not reflect the 
rates observed in practice.
Patients with Chronic Kidney Disease
Adverse reactions were determined based on pooled data from two active 
controlled studies of 1066 dialysis patients treated with OMONTYS and
542 treated with epoetin, including 938 exposed for at least 6 months and
825 exposed for greater than one year to OMONTYS. The population for 
OMONTYS was 20 to 93 years of age, 58.5% male, and the percentages of 
Caucasian, Black (including African Americans), and Asian patients were 57.9%, 
37.4%, and 3.1%, respectively. The median weight adjusted dose of OMONTYS 
was 0.07mg/kg and 113 U/week/kg of epoetin.
Table 3 summarizes the most frequent adverse reactions (≥ 10%) in dialysis 
patients treated with OMONTYS.















Respiratory, Thoracic and Mediastinal Disorders
Dyspnea 18.4% 19.4%
Cough 15.9% 16.6%
Injury, Poisoning and Procedural Complications
Arteriovenous Fistula
Site Complication 16.1% 16.6%
Procedural Hypotension 10.9% 12.5%
Nervous System Disorders
Headache 15.4% 15.9%
Musculoskeletal and Connective Tissue Disorders
Muscle Spasms 15.3% 17.2%
Pain in Extremity 10.9% 12.7%





General Disorders and Administration Site Conditions
Pyrexia 12.2% 14.0%
Metabolism and Nutrition Disorders
Hyperkalemia 11.4% 11.8%
Infections and Infestations
Upper Respiratory Tract Infection 11.0% 12.4%
Seizures have occurred in patients participating in OMONTYS clinical studies. During 
the first several months following initiation of OMONTYS, blood pressure and the 
presence of premonitory neurologic symptoms should be monitored closely.
Advise patients to contact their healthcare practitioner for new-onset seizures, 
premonitory symptoms, or change in seizure frequency.
Al lergic react ions have been reported in pat ients treated with 
OMONTYS. Discontinue OMONTYS and administer appropriate therapy if a 
serious allergic, anaphylactic or infusion-related reaction occurs.
Immunogenicity
Of the 2357 patients tested, 29 (1.2%) had detectable levels of peginesatide-
specific binding antibodies. There was a higher incidence of peginesatide-specific 
binding antibodies in patients dosed subcutaneously (1.9%) as compared to 
those dosed intravenously (0.7%). Peginesatide neutralizing antibodies were 
detected in vitro using a cell-based functional assay in 21 of these patients 
(0.9%).  In approximately half of all antibody-positive patients, the presence of 
antibodies was associated with declining hemoglobin levels, the requirement for 
increased doses of OMONTYS to maintain hemoglobin levels, and/or transfusion 
for anemia of CKD.  No cases of pure red cell aplasia (PRCA) developed in 
patients receiving OMONTYS during clinical trials.
DRUG INTERACTIONS
No formal drug/drug interaction studies have been performed. Peginesatide does 
not bind to serum albumin or lipoproteins as demonstrated in in vitro protein 
binding studies in rat, monkey and human sera. In vitro studies conducted with 
human hepatocytes or microsomes have shown no potential for peginesatide 
to induce or inhibit CYP450 enzymes.
USE IN SPECIFIC POPULATIONS
Pregnancy
Pregnancy Category C
There are no adequate and well-controlled studies in pregnant women. 
Peginesatide was teratogenic and caused embryofetal lethality when 
administered to pregnant animals at doses and/or exposures that resulted in 
polycythemia. OMONTYS should be used during pregnancy only if the potential 
benefit justifies the potential risk to the fetus.
Administration of peginesatide by intravenous injection to rats and rabbits during 
organogenesis was associated with embryofetal toxicity and malformations. 
Dosing was every third day in rats for a total of 5 doses and every fifth day 
in rabbits for a total of 3 doses (0.01 to 50 mg/kg/dose). In rats and rabbits, 
adverse embryofetal effects included reduced fetal weight, increased resorption, 
embryofetal lethality, cleft palate (rats only), sternum anomalies, unossification 
of sternebrae and metatarsals, and reduced ossification of some bones. 
Embryofetal toxicity was evident in rats at peginesatide doses of ≥ 1 mg/kg 
and the malformations (cleft palate and sternoschisis, and variations in blood 
vessels) were mostly evident at doses of ≥ 10 mg/kg. The dose of 1 mg/kg 
results in exposures (AUC) comparable to those in humans after intravenous 
administration at a dose of 0.35 mg/kg in patients on dialysis. In a separate 
embryofetal developmental study in rats, reduced fetal weight and reduced 
ossification were seen at a lower dose of 0.25 mg/kg. Reduced fetal weight 
and delayed ossification in rabbits were observed at ≥ 0.5 mg/kg/dose of 
peginesatide. In a separate embryofetal developmental study in rabbits, adverse 
findings were observed at lower doses and included increased incidence of fused 
sternebrae at 0.25 mg/kg. The effects in rabbits were observed at doses lower 
(5% - 50%) than the dose of 0.35 mg/kg in patients.
Nursing Mothers
It is not known whether peginesatide is excreted in human milk. Because 
many drugs are excreted into human milk, caution should be exercised when 
OMONTYS is administered to a nursing woman.
Pediatric Use
The safety and efficacy of OMONTYS in pediatric patients have not
been established.
Geriatric Use
Of the total number of dialysis patients in Phase 3 clinical studies of OMONTYS, 
32.5% were age 65 and over, while 13% were age 75 and over. No overall 
differences in safety or effectiveness were observed between these subjects 
and younger subjects.
OVERDOSAGE
OMONTYS overdosage can elevate hemoglobin levels above the desired level, 
which should be managed with discontinuation or reduction of OMONTYS 
dosage and/or with phlebotomy, as clinically indicated. Cases of severe 
hypertension have been observed following overdose with ESAs [see Warnings 
and Precautions].
PATIENT COUNSELING INFORMATION
See FDA-approved patient labeling (Medication Guide).
Marketed by:
Affymax, Inc.
Palo Alto, CA 94304
Distributed and Marketed by:
Takeda Pharmaceuticals America, Inc.
Deerfield, IL 60015
For more detailed information, see the full prescribing information for OMONTYS 
at www.omontys.com or contact Takeda Pharmaceuticals America, Inc.
OMONTYS is a trademark of Affymax, Inc. registered in the U.S. Patent and 
Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.
All other trademarks are the property of their respective owners.








More and more, the world depends on 
electronic information. The Internet has 
changed how we communicate, learn, 
and discover. In this issue of Kidney 
News, a series of articles explores the 
impact of the Internet on nephrology. 
Dealing with a deluge of information? 
Looking for new ways to connect? 
We have some answers.
The New World of Medical Tweeting
By Afreen I. Shariff, MD, and Tejas Desai, MD
Twitter has taken the world by storm. No one could have predicted that just 6 years after its inception Twitter would have 300 million users 
generating 300 million messages every day (1). If you are 
among the uninitiated, you should become familiar with 
how Twitter works and why it’s one of the most popular 
micro-blogging websites in the world.
Twitter is an open forum for sharing real-time in-
formation through “tweets.” A tweet is a short mes-
sage of 140 characters or less that can convey absolutely 
anything to your “followers” (people who subscribe to 
your “feed” of tweets). And with Twitter you aren’t just 
limited to text. Using third-party providers, you can 
insert Web addresses and link to photos, videos, and 
more. If you like a message you can copy and paste it 
to your followers, or in Twitter parlance “retweet it,” 
which is how a message is amplified. A recent study 
found that although 40 percent of messages on Twitter 
were pointless babble, 38 percent were conversation-
al—transferring information and spreading content 
(2).
The popularity of Twitter with the media, celebrities, 
and public figures is well documented, but members 
of the medical community seem hesitant to associate 
themselves with it. There could be many reasons for this: 
physicians may be unaware or unfamiliar with Twitter, 
they may be too busy, or they may fear potential privacy 
issues (3). Anticipating this, the American Medical As-
sociation has released a public statement about profes-
sionalism in social media:
“Participating in social networking and other 
similar internet opportunities can support physi-
cians’ personal expression, enable individual physi-
cians to have a professional presence online, foster 
collegiality and camaraderie within the profession, 
provide opportunity to widely disseminate public 
health messages and other health communica-
tion. Social networks, blogs, and other forms of 
communication online also create new challenges 
to the patient-physician relationship. Physicians 
should weigh a number of considerations when 
maintaining a presence online.”(4)
Because Twitter is a large pool of raw information and 
opinions, there are networking opportunities for those 
who can tap its potential. The news media analyze Twit-
ter posts to gain insights into elections, and politicians 
focus campaigns based on  public sentiment sifted from 
the site (5). This concept can be used in medical confer-
ences for networking within the medical community and 
with patients. Journals and conferences, including the 
American Society of Nephrology (ASN) Kidney Week, 
want to reach the widest possible audience, and using the 
large platform and audience Twitter provides ensures their 
important information is carried far and wide. By ana-
lyzing Twitter messages sent with conference or journal 
“hashtags” (short unique identifiers starting with “#”), 
it is possible to identify and understand patterns and 
how these impact a message’s reach. During ASN Kid-
ney Week 2011, we identified 172 unique tweeters who 
produced 993 tweets. Analysis of the content, citation, 
and sentiment have led to some interesting findings about 
conference-based tweeting and ways to improve confer-
ences’ impact and popularity.
This opens a door to advanced medical informat-
ics where physicians can interact with patients and 
network with consultants, students, and prospective 
residents. Twitter has many potential health care ap-
plications, such as recruiting potential organ donors, 
creating online communities for families with special 
needs, reporting new advances in therapy, initiating 
clinical case discussions among attending physicians 
and residents, and health marketing. 
In a recent JAMA study (6), investigators analyzed 
5156 tweets from physician accounts and found a ma-
jority (78 percent) identified themselves with their full 
name, with surgeons occupying the top spot for the 
highest number of tweets (39 percent) closely followed 
by internal medicine (29 percent). Physicians holding 
MDs (70.2 percent) were also more likely to tweet than 
their DO friends (2 percent) (6). Another group of 
researchers followed 125 students over a semester and 
found that those students in the Twitter-based educa-
tion group were more engaged in the subject and scored 
better than their other classmates (7). These data suggest 
that Twitter can be a strong educational tool. Research-
ers at East Carolina University are studying the use of 
Twitter to communicate during conferences and are 
developing strategies to better engage the student and 
physician populations. 
In summary, Twitter has the power to spread knowl-
edge and engage many people in conversations. It is the 
best one-to-many communication system to build your 
brand, network, give advice, or just have fun. Especially 
in an age of shrinking health care budgets, Twitter is an 
effective solution to the need for cheap mass communi-
cation (8). With Twitter, the future of communications 
is here, and it’s both free and easy. 
Afreen I. Shariff, MD, is with the department of internal 
medicine and Tejas Desai, MD, is with the division of ne-
phrology and hypertension, at East Carolina University in 
Greenville, NC.
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Suffering from information overload is a frustrating and all-too-com-mon condition today. If it isn’t hard 
enough to clear your overflowing email 
inbox, there’s the stress of staying on top 
of the blossoming number of journals 
and medical blogs in your field, papers 
uncovered through regular PubMed or 
Medline searches, not to mention the 
pressure of keeping up-to-date with the 
latest must-use social media tools. And 
yet, a small number of people seem to 
stay afloat while the vast majority of us 
are drowning in information. What’s 
their secret?
Every year, the Science Online con-
ference in North Carolina brings togeth-
er some of the most savvy digital natives 
in science and journalism. This provided 
a perfect opportunity for us to pose the 
question in the session Drowning in 
Information! How Can We Create Or-
ganization & Balance—Tools and Strate-
gies for Managing Information Overload 
(Science and Otherwise) (http://scio12.
wikispaces.com/D3S2d.+Drowning+in+ 
Information). Below are some of the 
main themes and tips that emerged for 
managing the data deluge that hits you 
on a daily basis.
Find	signals	among	the	noise	
You don’t need to subscribe to every-
thing! Find the information gathering 
tools that suit your content needs. If 
you regularly read journals and maga-
zines, subscribe to their RSS feeds so 
that you can read them all in one place. 
Google Reader (www.google.com/
reader) is a free, Web-based aggregator 
that allows you to organize, read, and 
search all of your favorite news sites and 
blogs in one place. If you like staying on 
top of the latest trends in a particular 
discipline, join Twitter (https://twitter.
com) and follow people in your field 
and/or people that share your interests 
and have your news curated. If you have 
an iPhone or iPad, the Flipboard app 
(http://flipboard.com) collates content 
from several social media sources.
Filter,	filter,	filter
For many people, reading and respond-
ing to email consumes the most time 
during a normal business day. Take 
back some of the time used to manage 
email by using folders to stay organ-
ized. In your email client, create specific 
folders based on topic, task, or person. 
Whether it’s for must-read content or 
for messages you can turn to at a later 
date, automate the task of sorting email 
based on keyword(s) and/or sender. This 
allows you to immediately focus on the 
message rather than on the action of 
sorting. Color-code emails to distin-
guish family and friends from meeting 
requests or table of content alerts, and 
do the same for RSS feeds, Twitter, and 
other online sources. Divide informa-
tion flows into folders or lists, such as 
“Daily reads” or “Weekend reads” or 
other categories that reflect your desired 
reading habits and content organiza-
tion. For more advanced management 
between different services and devices, 
use ifttt (If This Then That; http://ifttt.
com), which enables the creation of cus-
tomized, automated tasks.
Organize	and	archive
There are numerous free online tools 
that can help you store your informa-
tion, but three repeatedly came up in 
the discussion: Dropbox (https://www.
dropbox.com), which allows you to 
share files between your work and home 
computer; Mendeley (http://www.men-
deley.com), a reference manager that al-
lows you to organize, read, and annotate 
PDF documents; and Evernote (http://
www.evernote.com), a note-taking app 
which saves your most valuable notes, 
clippings, and photos on your compu-
ter and across all your mobile devices. 
Pinboard (http://pinboard.in) was also 
mentioned; although it is a paid service 
it allows you to bookmark and organize 
links, effortlessly saving those shared via 
Twitter.
Get	into	the	habit
It’s easy to give up on a tool within days, 
especially if it becomes stressful to deal 
with its backlog after a deadline, con-
ference or, heaven forbid, a vacation. 
People recommended throwing yourself 
into a method for 30 days and see if it 
works before ditching it. And try regu-
lar cleansing sessions—for instance, try 
clearing your information streams every 
Sunday evening. That way, you’ll start 
each week without the pressure or guilt 
of looking at old content that you are 
unlikely to read anyway. 
Walter Jessen is a computational biologist, 
knowledge curator, and Web developer at 
Walter Jessen Discovery New Media (http://
www.walterjessen.com).  Simon Frantz is 
the Science/Technology Features editor at 
BBC Future (http://www.bbc.com/future).
The Journal of the American Medical Association has reported that one in nine Americans now have chronic kidney disease, and that figure is be-lieved to be growing. At the same time many publications (among them, 
Kidney News) are tracking a drop in the number of nephrologists entering the 
field, and others have documented the strain on those already practicing as dialy-
sis resources are stretched thin. 
As awareness of kidney disease within the gen-
eral population increases, so will nephrologists’ 
need for a safe, efficient, and Health Insurance 
Portability and Accountability Act (HIPAA)–
compliant system for securely managing incom-
ing referrals and discussing patient information 
with a treatment team. Although doctors them-
selves are often early adopters of information 
technology—81 percent now own a smartphone, 
for example—medicine as a whole has been slow 
to catch up. Email and Short Message Service 
(SMS), for instance, are not considered HIPAA 
secure, a point that the Joint Commission on Ac-
creditation of Healthcare Organizations emphasized in November 2011 when it 
issued a ban on texting. This, of course, leaves physicians reliant on telephones, 
pagers, and faxes to communicate patient information. 
Doximity was founded to address what we see as one of the next big challeng-
es in health care—facilitating communication among physicians. Our company 
has been described as a kind of LinkedIn for doctors, and with nearly 30,000 
physicians signed up, we’re already the largest medical professional network in 
the country. Enabling doctors to find and make connections in their practices 
and with alumni is valuable in itself, but what may be even more essential to our 
specific community is a private and HIPAA-secure method 
of exchanging information. We assign dual passwords to 
each user so each message is encrypted end to end. And 
because Doximity has been optimized for both smart-
phones and tablets,  messages can be sent, and referrals made, from the operating 
room—or far from the nearest hospital—as easily as from a computer. 
Equally integral to safe communication is real-name interaction. At Doxim-
ity, we verify each of our users. We believe that ensuring every member’s identity 
creates a framework of trust, expertise, and professionalism that reflects the ef-
fective physician interaction in the real world. The difference, of course, is that 
these communications are increasingly happening as ongoing written discussions 
across thousands of miles.
In many ways, our newest feature, iRounds, grew out of these changes. Not 
unlike social networking sites such as Twitter, Facebook, and Google, iRounds 
allows users to tap into larger communities to discuss patient cases, new research, 
emerging medical technologies, and more.
“Doximity offers an easy way to keep up to date on the latest news, best 
blog posts, and journal articles from our specialty,” said Joshua Schwimmer, 
MD, a nephrologist at Lenox Hill Hospital and The Mount Sinai Hospital in 
New York. “For example, a review article on focal segmental glomerulosclerosis 
(FSGS) in the New England Journal of Medicine was the basis for a discussion 
among multiple specialties about the presentation of FSGS, the differences 
between FSGS and diabetic nephropathy, and the indications for renal biopsy. 
The easy-access via smartphone and the Web, the user-friendly design, and the 
ready availability of physicians’ credentials makes it simple to collaborate and 
learn from your colleagues.” 
Sara Reistad-Long is affiliated with Doximity.
How to Deal with Information Overload 
Doximity
By Walter Jessen, PhD, and Simon Frantz
By Sara Reistad-Long
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Understanding the true value of a scholar’s research and output is no small feat. Although it’s fairly 
straightforward to track the number of 
publications or total dollar amount of 
awarded funding, it can be a greater chal-
lenge to assess the reach of scholarly efforts 
and determine how others are utilizing 
the research results. Metrics for assessing 
research performance, quality, and impact 
cover a wide range of the scholarly ecosys-
tem and are used for a variety of purposes: 
individual career planning, promotion, 
and tenure; benchmarking to track group 
or institutional performance; marketing 
and strategic planning purposes; and re-
porting research outcomes to the public.
Author-level	metrics
Author-level metrics allow individuals to 
track their scholarly output and serve as 
a reflection of a researcher’s productivity. 
Enumerating such things as the number 
of publications in the scholarly literature, 
number of books published, and number 
and amount of funding awards can all serve 
to understand the efforts of individual re-
searchers. One commonly used metric is 
the Hirsch index (h index). The h index, 
developed by Jorge E. Hirsch, PhD, in 
2005 (1), offers a numeric index to meas-
ure the productivity and impact of a given 
researcher. The h index is a quantitative 
metric based on analysis of publication 
data, using publications and citations to 
provide “an estimate of the importance, 
significance, and broad impact of a scien-
tist’s cumulative research contributions” 
(1). According to Hirsch, the h index is 
defined as follows: “A scientist has index h 
if h of his or her Np papers have at least h 
citations each and the other (Np – h) pa-
pers have ≤h citations each” (1), where Np 
is total number of papers published.
As an example, an h index of 10 means 
that among all publications by one author, 
10 of these publications have received at 
least 10 citations each. The h index is but 
one metric for author-level assessment. 
No single metric is sufficient for measur-
ing performance, quality, or impact by an 
author; indeed, the discovery of a scholar’s 
most impactful work may be gleaned only 
through qualitative forms of assessment 
that do not rely solely on publication data.
Article-level	metrics
Citation counts are perhaps the most fre-
quently used metric at the article level. A 
citation is a reference to a specific publi-
cation. The inherent assumption is that 
significant articles will have high numbers 
of citations. Further analysis is required to 
discover why select publications garner a 
higher citation rate than others. Many da-
tabases provide tools for authors to track 
citations to their work, with some offering 
citation maps that can be downloaded for 
reporting purposes.
A growing article-level metric is based 
on the usage of a publication; several jour-
nals and third-party service providers are 
making it possible to assess the Web-based 
use and subsequent dissemination of indi-
vidual articles. The Public Library of Sci-
ence (PLoS) journals offer perhaps the most 
highly developed publisher-based platform 
for this type of tracking. Articles published 
in PLoS journals include an article-level 
metrics tab that shows such details as arti-
cle usage statistics (e.g., HTML page views, 
PDF and XML downloads, and accesses 
from PubMed Central; number of users 
via Mendeley; and number of Facebook 
mentions); citations from the scholarly lit-
erature (currently from CrossRef, PubMed 
Central, SciVerse Scopus, and Web of Sci-
ence); social bookmarks from CiteULike 
and Connotea; PLoS reader evaluation 
(i.e., readers’ feedback on the article in the 
form of comments, notes, and star ratings); 
and discussion of the article in blogs (2). 
These alternative metrics (or “altmetrics” as 
they are commonly known) for articles and 
even datasets and presentations are becom-
ing easier to track via Web services such as 
Total-Impact (http://total-impact.org) and 
Altmetric (http://www.postgenomic.com), 
who offers explorer and browser-based 
bookmarklet applications.
Journal-level	metrics
Journals are also assessed by different crite-
ria. The impact factor, listed in Thomson 
Reuters’ Journal Citation Reports, assigns 
journals a numeric score based on the fre-
quency with which the average article in the 
journal is cited over a set period of time (3). 
Whereas the impact factor tracks straight 
citations, the Eigenfactor score (http://
www.eigenfactor.org) is derived from a for-
mula based on citations from a journal over 
a 5-year period, with citations from highly 
ranked journals given more weight. Journal 
self-citations are not included in the Eigen-
factor score, unlike the impact factor score.
A caveat of note for journal-level met-
rics: specialized journals or those published 
by societies may disseminate your work 
more efficiently to colleagues in your field 
than a “high-impact” general-interest sci-
ence journal. Reaching your intended au-
dience is the surest way to enhance the vis-
ibility and impact of your research. 
Going	beyond	the	metrics:	the	
Becker	model
It is tempting to use these metrics as an 
objective way to assign value or worth to a 
researcher’s output or to an individual jour-
nal. Although these metrics can be helpful 
in understanding research efforts, they can-
not be evaluated in a vacuum. To under-
stand the true impact of research, metrics 
derived from publication data must be 
supplemented with indicators that dem-
onstrate tangible outcomes such as clinical 
implementation, benefit to the commu-
nity, influence on legislation or policy, and 
economic benefit. Publication data alone 
do not provide a full narrative of research 
impact, nor are they predictive of meaning-
ful health outcomes.
The Becker Medical Library Model for 
Assessment of Research Impact (4,5) serves 
as a framework to quantify and document 
research impact based on research outputs 
and activities. It includes resources for lo-
cating evidence of research impact and 
strategies for enhancing research impact. 
The site offers reporting templates, a glos-
sary, and examples of relevant indicators of 
impact across the research process as well as 
a sample of a completed report. The use of 
publication data in tandem with the Beck-
er Model provides a more robust overview 
of the impact of research to accomplish a 
host of higher-order activities that are criti-
cal in today’s biomedical research world, 
including the following:
• Justification of future requests for funding
• Quantification of return on research in-
vestment
• Discovery of how research findings are 
being used
• Promotion and tenure activities
• Identification of possible collaborators
• Demonstration that research findings are 
resulting in meaningful health outcomes
• Discovery of community benefit as a 
result of research findings 
1.  Hirsch JE. An index to quantify an 
individual’s scientific research out-
put. Proc Natl Acad Sci U S A 2005; 
102:16569–16572.
2.  Public Library of Science. Article-
level metrics. http://article-level-
metrics.plos.org.
3.  Thomson Reuters. The Thomson Reu-
ters impact factor. http://thomsonreuters.
com/products_services/science/free/es-
says/impact_factor.
4.  Sarli CC, Dubinsky EK, Holmes KL. 
Beyond citation analysis: a model for 
assessment of research impact. J Med 
Libr Assoc 2010; 98:17–23. 
5.  Bernard Becker Medical Library. As-
sessing the impact of research. The 
Becker Medical Library Model for as-
sessment of research impact. https://
becker.wustl.edu/impact/assessment/
index.html.
Kristi L. Holmes and Cathy C. Sarli are af-
filiated with the Bernard Becker Medical Li-
brary, School of Medicine, Washington Uni-
versity, St. Louis.
By Kristi L. Holmes and Cathy C. Sarli
Understanding Research Impact
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20 Strategies to Enhance the Impact of Your Research
1. Authors should use the same variation of their 
name consistently throughout their academic ca-
reers. If your name is a common one, consider add-
ing your full middle name to distinguish it from 
other authors. Consistency enhances retrieval.
2. Consider adding the name of the research study 
or your center, institute, division, or program as a 
corporate author, and use the same name consist-
ently. This will allow for enhanced retrieval of pub-
lications generated by a particular research study or 
center, institute, division, or program in a database 
or resource search. See the National Library of 
Medicine’s Fact Sheet: Authorship in MEDLINE (1). 
3. Assign Medical Subject Headings (MeSH) terms 
to the manuscript. Contact your health sciences 
library for assistance with MeSH terms.
4. Formulate a concise, well-constructed title and 
abstract. Include crucial key words in the abstract. 
See Wiley-Blackwell’s Optimizing Your Article for 
Search Engines (2).
5. Retain the rights to your manuscripts to allow for 
maximum flexibility in reusing your work. 
6. If your work involves potential translational medi-
cine applications, include a discussion of how the 
research could translate to clinical outcomes. “Im-
pact of journal articles will be improved if they 
provide a direct line of reasoning for how findings 
might translate into useful information for real-
world behaviors or technologies. This will enhance 
the probability that the article will affect public 
policy and thus increase its impact.” (3)
7. Submit the manuscript to a digital subject reposi-
tory or your institution’s facility, if they have one. 
Contact your health sciences library for assistance 
with identifying appropriate locations.
8. Publish your work in an open access journal. Open 
access journals allow authors to retain rights to 
their work, which allows for other options for dis-
semination of the research. Open access articles 
may garner greater impact than traditional publi-
cation models (4). 
9. Set up a website devoted to the research project, 
and post manuscripts of publications, conference 
abstracts, and supplemental materials—such as im-
ages, illustrations, slides, specimens, and progress 
reports—on the site.
10. Share the research data and deposit it in appropri-
ate repositories, such as GenBank (http://www.
ncbi.nlm.nih.gov/genbank) and other databases at 
the National Center for Biotechnology Informa-
tion, or with journal publishers willing to post the 
data. Sharing of this information may lead to more 
rapid analysis and identification of genetic contri-
butions to diseases and medical conditions. One 
study (5) has demonstrated a correlation between 
shared research data and an increased number of 
citations. 
11. Present preliminary research findings at a meeting 
or conference, and after the event consider mak-
ing your figures available through Figshare (http:// 
figshare.com) and your presentation materials 
available in your institutional repository or on a 
slide-sharing site such as SlideShare (www.slide-
share.net) so that others may discover and share 
your knowledge.
12. Consider communicating information about your 
research via Twitter (https://twitter.com). Twitter 
provides an efficient platform for communicating 
and consuming science. For some practical guid-
ance on getting started and some background, see 
Twitter 101: How should I get started using Twitter? 
(6). To get a better idea of how and why scientists 
and physicians are using Twitter, you might find 
What is Twitter and Why Scientists Need to Use It 
(7), How Could Twitter Influence Science (and Why 
Scientists Are on Board) (8), and Physicians on Twit-
ter (9) of interest, as well.
13. Research is not just text and figures. Create a 
podcast describing the research project, and sub-
mit it to YouTube (http://www.youtube.com) 
or Vimeo (http://vimeo.com). The Washington 
University YouTube channel offers good exam-
ples (http://www.youtube.com/user/wustlpa#p/c/
F4A14AEE489425B0). Another option for dis-
tributing podcasts is BioMed Central (http://www. 
biomedcentral.com), an organization that recog-
nizes video as an increasingly important way for 
researchers to communicate their results and that 
welcomes podcast submissions. Links to these pod-
casts are located on the BioMed Central YouTube 
channel.
14. Issue press releases for significant findings, and 
partner with your organization’s media office to 
deliver findings to local media outlets.
15. If there is a website for the study, provide informa-
tion tailored for consumers. According to the 2009 
Pew Internet & American Life Project report (10), 
61 percent of Americans use the Internet for health 
information.
16. Conduct outreach visits and/or provide seminars 
to other institutions, scientists, practicing physi-
cians, and health care providers to discuss your re-
search project.
17. Consider discussing the results of your research 
with policy makers and other governing bodies 
that issue policies, guidelines, and standards. See 
Feeding your Research into the Policy Debate (11) for 
a review of the pros and cons of doing this. 
18. Keep your profile data up to date on social net-
working sites aimed at scientists, researchers, and/
or physicians. Inquire about these tools within your 
organization. Some highly adopted institution-
wide platforms include VIVO (http://vivoweb.org) 
and Profiles (http://profiles.catalyst.harvard.edu). 
These institutional efforts leverage structured data 
about researchers to provide current and validated 
information that can be used to visualize research 
efforts and identify new collaborators. 
19. Sign up for other social networking sites to in-
crease your visibility and connect with colleagues. 
Some useful sites are ResearcherID (http://www. 
researcherid.com) and LinkedIn (http://www.
linkedin.com). Sites such as Nature Network 
(http://network.nature.com) allow and encourage 
interaction between users. Social network tools 
provide a forum for disseminating your research, 
promoting discussion of your work, sharing scien-
tific information, and forming new partnerships.
20. Alternative metrics allow users to understand how 
their work is being used in the online world via 
bookmarks and links to the article or data, conver-
sations on Twitter, in blogs about the work, and in 
the various methods of sharing and storing con-
tent. Some great sites for viewing these “altmet-
rics” include Total-Impact, ReaderMeter (http://
readermeter.org), and resources at Altmetric, 
including an explorer and a bookmarklet that is 
easily incorporated into your Web browser book-
mark bar. 
References
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factsheets/authorship.html.
2.  Wiley-Blackwell. Optimizing your article for 
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bauthor/seo.asp.
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4.  The Open Citation Project. The effect of open ac-
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Adapted from the Becker Medical Library Model for As-
sessment of Research Impact, available at https://becker.
wustl.edu/impact-assessment/strategies.
Improving access to, and retrieval of, your research articles is the surest way to enhance their 
impact. Repetition, consistency, and an awareness of the intended audience form the basis of 
most of the following strategies in areas related to preparation for publication, dissemination 
of content, and keeping track of your research. 
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NCCN Guidelines® Category 1 recommendation4
•  As a fi rst-line therapy for relapsed or Stage IV unresectable RCC of predominant clear cell histology. These Guidelines also include 
therapies other than VOTRIENT as fi rst-line treatment options
WARNING: HEPATOTOXICITY
Severe and fatal hepatotoxicity has been observed in clinical studies. Monitor hepatic function 
and interrupt, reduce, or discontinue dosing as recommended. See “Warnings and Precautions,” 
Section 5.1, in complete Prescribing Information.
VOTRIENT: Safety Profi le Summary1
•  Most common adverse events observed with VOTRIENT were diarrhea, hypertension, hair color changes
(depigmentation), nausea, anorexia, and vomiting
— Grade 3/4 fatigue occurred in 2% of patients; all grades, 19% of patients
— Grade 3/4 asthenia occurred in 3% of patients; all grades, 14% of patients   
•  For any individual adverse reaction in the VOTRIENT arm, the rate of Grade 3/4 adverse events is ≤4%
 Most common laboratory abnormalities were ALT and AST increases1
•  Grade 3 ALT increases occurred in 10% of patients; grade 4, 2% of patients; 
all grades, 53% of patients
•  In clinical trials, 92.5% of all transaminase elevations of any grade occurred 
in the fi rst 18 weeks of treatment with VOTRIENT
•  Monitor serum liver tests before initiation of treatment with VOTRIENT and at least 
once every 4 weeks for at least the fi rst 4 months of treatment or as clinically indicated. 
Periodic monitoring should then continue after this time period
In Advanced Renal Cell Carcinoma... Move Forward With VOTRIENT
In a phase 3, randomized, double-blind, placebo-controlled trial, VOTRIENT provided signifi cant improvement 
in progression-free survival (PFS) in both treatment-naïve and cytokine-pretreated patients with advanced RCC1,2
•  Hypothyroidism: Hypothyroidism was reported as an 
adverse reaction in 26/586 (4%). Monitoring of thyroid 
function tests is recommended.
•  Proteinuria: Monitor urine protein. Proteinuria was 
reported in 44/586 (8%) (Grade 3, 5/586 [<1%] and 
Grade 4, 1/586 [<1%]). Baseline and periodic urinalysis 
during treatment is recommended. Discontinue for 
Grade 4 proteinuria.
•  Pregnancy Category D: VOTRIENT can cause fetal 
harm when administered to a pregnant woman. 
Women of childbearing potential should be advised of 
the potential hazard to the fetus and to avoid becoming 
pregnant while taking VOTRIENT.
•  Drug Interactions: CYP3A4 Inhibitors (eg, 
ketoconazole, ritonavir, clarithromycin): Avoid use of 
strong inhibitors. Consider dose reduction of VOTRIENT 
when administered with strong CYP3A4 inhibitors. 
CYP3A4 Inducers (such as rifampin): Consider an 
alternate concomitant medication with no or minimal 
enzyme induction potential or avoid VOTRIENT.
CYP Substrates: Concomitant use of VOTRIENT with 
agents with narrow therapeutic windows that are 
metabolized by CYP3A4, CYP2D6, or CYP2C8 is 
not recommended.
Concomitant use of VOTRIENT and simvastatin 
increases the incidence of ALT elevations. If a patient 
develops ALT elevations, follow dosing guidelines 
for VOTRIENT, consider alternatives to VOTRIENT or 
discontinuing simvastatin. There are insuffi cient data 
to assess the risk of concomitant administration of 
alternative statins and VOTRIENT.  
•  Adverse Reactions: The most common adverse 
reactions (>20%) for VOTRIENT versus placebo were 
diarrhea (52% vs 9%), hypertension (40% vs 10%), 
hair color changes (depigmentation) (38% vs 3%), 
nausea (26% vs 9%), anorexia (22% vs 10%), and 
vomiting (21% vs 8%). 
Laboratory abnormalities occurring in >10% of patients 
and more commonly (≥5%) in the VOTRIENT arm 
versus placebo included increases in ALT (53% vs 22%), 
AST (53% vs 19%), glucose (41% vs 33%), and total 
bilirubin (36% vs 10%); decreases in phosphorus (34% 
vs 11%), sodium (31% vs 24%), magnesium (26% vs 
14%), and glucose (17% vs 3%); and leukopenia (37% 
vs 6%), neutropenia (34% vs 6%), thrombocytopenia 
(32% vs 5%), and lymphocytopenia (31% vs 24%). 
VOTRIENT has been associated with cardiac 
dysfunction (such as a decrease in ejection fraction 
and congestive heart failure) in patients with various 
cancer types, including RCC. In the overall safety 
population for RCC (N=586), cardiac dysfunction 
was observed in 4/586 patients (<1%).
Please see Brief Summary of Prescribing 
Information on adjacent pages.
References: 1. VOTRIENT® (pazopanib) Tablets [package insert]. 
Research Triangle Park, NC: GlaxoSmithKline; 2012. 2. Sternberg 
CN, et al. J Clin Oncol. 2010;28(6):1061-1068. 3. Data on fi le, 
GlaxoSmithKline. 4. Referenced with permission from The NCCN 
Clinical Practice Guidelines in Oncology® for Kidney Cancer V.2.2012. 
©National Comprehensive Cancer Network, Inc 2012. All rights 
reserved. Accessed March 22, 2012. To view the most recent and 
complete version of the guideline, go online to www.nccn.org. 
NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN 
GUIDELINES®, and all other NCCN content are trademarks owned by 
the National Comprehensive Cancer Network, Inc.
INDICATION
VOTRIENT is indicated for the treatment of patients 
with advanced renal cell carcinoma (RCC).
IMPORTANT SAFETY INFORMATION 
WARNING: HEPATOTOXICITY 
Severe and fatal hepatotoxicity has been 
observed in clinical studies. Monitor hepatic 
function and interrupt, reduce, or discontinue 
dosing as recommended. See “Warnings and 
Precautions,” Section 5.1, in complete Prescribing 
Information.
•  Hepatic Effects: Patients with pre-existing hepatic 
impairment should use VOTRIENT with caution. 
In patients with pre-existing moderate hepatic 
impairment, the starting dose of VOTRIENT should 
be reduced to 200 mg per day or alternatives to 
VOTRIENT should be considered. Treatment with 
VOTRIENT is not recommended in patients with severe 
hepatic impairment. Increases in serum transaminase 
levels (ALT, AST) and bilirubin were observed. Severe 
and fatal hepatotoxicity has occurred. Transaminase 
elevations occur early in the course of treatment 
(92.5% of all transaminase elevations of any grade 
occurred in the fi rst 18 weeks). Concomitant use of 
VOTRIENT and simvastatin increases the risk of 
ALT elevations and should be undertaken with 
caution [see Drug Interactions]. Before the initiation 
of treatment and regularly during treatment, monitor 
hepatic function and interrupt, reduce, or 
discontinue dosing as recommended.  
•  QT Prolongation and Torsades de Pointes: 
Prolonged QT intervals and arrhythmias, including 
torsades de pointes, have been observed with 
VOTRIENT. Use with caution in patients at higher 
risk of developing QT interval prolongation, in 
patients taking antiarrhythmics or other medications 
that may prolong QT interval, and those with 
relevant pre-existing cardiac disease. Baseline 
and periodic monitoring of electrocardiograms 
and maintenance of electrolytes within the normal 
range should be performed.
•  Hemorrhagic Events: Fatal hemorrhagic events have 
been reported (all Grades [16%] and Grades 3 to 5 
[2%]). VOTRIENT has not been studied in patients 
who have a history of hemoptysis, cerebral, or clinically 
signifi cant gastrointestinal hemorrhage in the past 
6 months and should not be used in those patients.
•  Arterial Thrombotic Events: Arterial thrombotic 
events have been observed and can be fatal. In clinical 
RCC studies of VOTRIENT, myocardial infarction, 
angina, ischemic stroke, and transient ischemic attack 
(all Grades [3%] and Grades 3 to 5 [2%]) were 
observed. Use with caution in patients who are at 
increased risk for these events.
•  Gastrointestinal Perforation and Fistula: 
Gastrointestinal perforation or fi stula has occurred. 
Fatal perforation events have occurred. Use with 
caution in patients at risk for gastrointestinal 
perforation or fi stula. Monitor for symptoms of 
gastrointestinal perforation or fi stula.
•  Hypertension: Hypertension, including hypertensive 
crisis, has been observed. Blood pressure should be 
well-controlled prior to initiating VOTRIENT. Monitor 
for hypertension and treat as needed. Hypertension 
was observed in 47% of patients with RCC treated 
with VOTRIENT. Hypertension occurs early in the 
course of treatment (39% of cases occurred by Day 
9 and 88% of cases occurred in the fi rst 18 weeks). 
In the case of persistent hypertension despite anti-
hypertensive therapy, the dose of VOTRIENT may be 
reduced. VOTRIENT should be discontinued if there 
is evidence of hypertensive crisis or if hypertension is 
severe and persistent despite anti-hypertensive therapy 
and dose reduction of VOTRIENT.
•  Wound Healing: VOTRIENT may impair wound 
healing. Temporary interruption of therapy with 
VOTRIENT is recommended in patients undergoing 
surgical procedures. VOTRIENT should be 
discontinued in patients with wound dehiscence. 
All patients
9.2 months
(95% CI, 7.4-12.9) 
overall median PFS with VOTRIENT (n=290) 
vs 4.2 months (95% CI, 2.8-4.2) 
with placebo (n=145) (P<0.001)1,3
Treatment-naïve patients
11.1 months 
(95% CI, 7.4-14.8) 
median PFS with VOTRIENT (n=155) 
vs 2.8 months (95% CI, 1.9-5.6) 
with placebo (n=78) (P<0.001)1,3
Cytokine-pretreated patients 
7.4 months
(95% CI, 5.6-12.9) 
median PFS with VOTRIENT (n=135) 
vs 4.2 months (95% CI, 2.8-5.6) 
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NCCN Guidelines® Category 1 recommendation4
•  As a fi rst-line therapy for relapsed or Stage IV unresectable RCC of predominant clear cell histology. These Guidelines also include 
therapies other than VOTRIENT as fi rst-line treatment options
WARNING: HEPATOTOXICITY
Severe and fatal hepatotoxicity has been observed in clinical studies. Monitor hepatic function 
and interrupt, reduce, or discontinue dosing as recommended. See “Warnings and Precautions,” 
Section 5.1, in complete Prescribing Information.
VOTRIENT: Safety Profi le Summary1
•  Most common adverse events observed with VOTRIENT were diarrhea, hypertension, hair color changes
(depigmentation), nausea, anorexia, and vomiting
— Grade 3/4 fatigue occurred in 2% of patients; all grades, 19% of patients
— Grade 3/4 asthenia occurred in 3% of patients; all grades, 14% of patients   
•  For any individual adverse reaction in the VOTRIENT arm, the rate of Grade 3/4 adverse events is ≤4%
 Most common laboratory abnormalities were ALT and AST increases1
•  Grade 3 ALT increases occurred in 10% of patients; grade 4, 2% of patients; 
all grades, 53% of patients
•  In clinical trials, 92.5% of all transaminase elevations of any grade occurred 
in the fi rst 18 weeks of treatment with VOTRIENT
•  Monitor serum liver tests before initiation of treatment with VOTRIENT and at least 
once every 4 weeks for at least the fi rst 4 months of treatment or as clinically indicated. 
Periodic monitoring should then continue after this time period
In Advanced Renal Cell Carcinoma... Move Forward With VOTRIENT
In a phase 3, randomized, double-blind, placebo-controlled trial, VOTRIENT provided signifi cant improvement 
in progression-free survival (PFS) in both treatment-naïve and cytokine-pretreated patients with advanced RCC1,2
•  Hypothyroidism: Hypothyroidism was reported as an 
adverse reaction in 26/586 (4%). Monitoring of thyroid 
function tests is recommended.
•  Proteinuria: Monitor urine protein. Proteinuria was 
reported in 44/586 (8%) (Grade 3, 5/586 [<1%] and 
Grade 4, 1/586 [<1%]). Baseline and periodic urinalysis 
during treatment is recommended. Discontinue for 
Grade 4 proteinuria.
•  Pregnancy Category D: VOTRIENT can cause fetal 
harm when administered to a pregnant woman. 
Women of childbearing potential should be advised of 
the potential hazard to the fetus and to avoid becoming 
pregnant while taking VOTRIENT.
•  Drug Interactions: CYP3A4 Inhibitors (eg, 
ketoconazole, ritonavir, clarithromycin): Avoid use of 
strong inhibitors. Consider dose reduction of VOTRIENT 
when administered with strong CYP3A4 inhibitors. 
CYP3A4 Inducers (such as rifampin): Consider an 
alternate concomitant medication with no or minimal 
enzyme induction potential or avoid VOTRIENT.
CYP Substrates: Concomitant use of VOTRIENT with 
agents with narrow therapeutic windows that are 
metabolized by CYP3A4, CYP2D6, or CYP2C8 is 
not recommended.
Concomitant use of VOTRIENT and simvastatin 
increases the incidence of ALT elevations. If a patient 
develops ALT elevations, follow dosing guidelines 
for VOTRIENT, consider alternatives to VOTRIENT or 
discontinuing simvastatin. There are insuffi cient data 
to assess the risk of concomitant administration of 
alternative statins and VOTRIENT.  
•  Adverse Reactions: The most common adverse 
reactions (>20%) for VOTRIENT versus placebo were 
diarrhea (52% vs 9%), hypertension (40% vs 10%), 
hair color changes (depigmentation) (38% vs 3%), 
nausea (26% vs 9%), anorexia (22% vs 10%), and 
vomiting (21% vs 8%). 
Laboratory abnormalities occurring in >10% of patients 
and more commonly (≥5%) in the VOTRIENT arm 
versus placebo included increases in ALT (53% vs 22%), 
AST (53% vs 19%), glucose (41% vs 33%), and total 
bilirubin (36% vs 10%); decreases in phosphorus (34% 
vs 11%), sodium (31% vs 24%), magnesium (26% vs 
14%), and glucose (17% vs 3%); and leukopenia (37% 
vs 6%), neutropenia (34% vs 6%), thrombocytopenia 
(32% vs 5%), and lymphocytopenia (31% vs 24%). 
VOTRIENT has been associated with cardiac 
dysfunction (such as a decrease in ejection fraction 
and congestive heart failure) in patients with various 
cancer types, including RCC. In the overall safety 
population for RCC (N=586), cardiac dysfunction 
was observed in 4/586 patients (<1%).
Please see Brief Summary of Prescribing 
Information on adjacent pages.
References: 1. VOTRIENT® (pazopanib) Tablets [package insert]. 
Research Triangle Park, NC: GlaxoSmithKline; 2012. 2. Sternberg 
CN, et al. J Clin Oncol. 2010;28(6):1061-1068. 3. Data on fi le, 
GlaxoSmithKline. 4. Referenced with permission from The NCCN 
Clinical Practice Guidelines in Oncology® for Kidney Cancer V.2.2012. 
©National Comprehensive Cancer Network, Inc 2012. All rights 
reserved. Accessed March 22, 2012. To view the most recent and 
complete version of the guideline, go online to www.nccn.org. 
NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN 
GUIDELINES®, and all other NCCN content are trademarks owned by 
the National Comprehensive Cancer Network, Inc.
INDICATION
VOTRIENT is indicated for the treatment of patients 
with advanced renal cell carcinoma (RCC).
IMPORTANT SAFETY INFORMATION 
WARNING: HEPATOTOXICITY 
Severe and fatal hepatotoxicity has been 
observed in clinical studies. Monitor hepatic 
function and interrupt, reduce, or discontinue 
dosing as recommended. See “Warnings and 
Precautions,” Section 5.1, in complete Prescribing 
Information.
•  Hepatic Effects: Patients with pre-existing hepatic 
impairment should use VOTRIENT with caution. 
In patients with pre-existing moderate hepatic 
impairment, the starting dose of VOTRIENT should 
be reduced to 200 mg per day or alternatives to 
VOTRIENT should be considered. Treatment with 
VOTRIENT is not recommended in patients with severe 
hepatic impairment. Increases in serum transaminase 
levels (ALT, AST) and bilirubin were observed. Severe 
and fatal hepatotoxicity has occurred. Transaminase 
elevations occur early in the course of treatment 
(92.5% of all transaminase elevations of any grade 
occurred in the fi rst 18 weeks). Concomitant use of 
VOTRIENT and simvastatin increases the risk of 
ALT elevations and should be undertaken with 
caution [see Drug Interactions]. Before the initiation 
of treatment and regularly during treatment, monitor 
hepatic function and interrupt, reduce, or 
discontinue dosing as recommended.  
•  QT Prolongation and Torsades de Pointes: 
Prolonged QT intervals and arrhythmias, including 
torsades de pointes, have been observed with 
VOTRIENT. Use with caution in patients at higher 
risk of developing QT interval prolongation, in 
patients taking antiarrhythmics or other medications 
that may prolong QT interval, and those with 
relevant pre-existing cardiac disease. Baseline 
and periodic monitoring of electrocardiograms 
and maintenance of electrolytes within the normal 
range should be performed.
•  Hemorrhagic Events: Fatal hemorrhagic events have 
been reported (all Grades [16%] and Grades 3 to 5 
[2%]). VOTRIENT has not been studied in patients 
who have a history of hemoptysis, cerebral, or clinically 
signifi cant gastrointestinal hemorrhage in the past 
6 months and should not be used in those patients.
•  Arterial Thrombotic Events: Arterial thrombotic 
events have been observed and can be fatal. In clinical 
RCC studies of VOTRIENT, myocardial infarction, 
angina, ischemic stroke, and transient ischemic attack 
(all Grades [3%] and Grades 3 to 5 [2%]) were 
observed. Use with caution in patients who are at 
increased risk for these events.
•  Gastrointestinal Perforation and Fistula: 
Gastrointestinal perforation or fi stula has occurred. 
Fatal perforation events have occurred. Use with 
caution in patients at risk for gastrointestinal 
perforation or fi stula. Monitor for symptoms of 
gastrointestinal perforation or fi stula.
•  Hypertension: Hypertension, including hypertensive 
crisis, has been observed. Blood pressure should be 
well-controlled prior to initiating VOTRIENT. Monitor 
for hypertension and treat as needed. Hypertension 
was observed in 47% of patients with RCC treated 
with VOTRIENT. Hypertension occurs early in the 
course of treatment (39% of cases occurred by Day 
9 and 88% of cases occurred in the fi rst 18 weeks). 
In the case of persistent hypertension despite anti-
hypertensive therapy, the dose of VOTRIENT may be 
reduced. VOTRIENT should be discontinued if there 
is evidence of hypertensive crisis or if hypertension is 
severe and persistent despite anti-hypertensive therapy 
and dose reduction of VOTRIENT.
•  Wound Healing: VOTRIENT may impair wound 
healing. Temporary interruption of therapy with 
VOTRIENT is recommended in patients undergoing 
surgical procedures. VOTRIENT should be 
discontinued in patients with wound dehiscence. 
All patients
9.2 months
(95% CI, 7.4-12.9) 
overall median PFS with VOTRIENT (n=290) 
vs 4.2 months (95% CI, 2.8-4.2) 
with placebo (n=145) (P<0.001)1,3
Treatment-naïve patients
11.1 months 
(95% CI, 7.4-14.8) 
median PFS with VOTRIENT (n=155) 
vs 2.8 months (95% CI, 1.9-5.6) 
with placebo (n=78) (P<0.001)1,3
Cytokine-pretreated patients 
7.4 months
(95% CI, 5.6-12.9) 
median PFS with VOTRIENT (n=135) 
vs 4.2 months (95% CI, 2.8-5.6) 
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Many patients approaching end stage re-
nal disease (ESRD) are willing to accept 
significant reductions in survival to avoid 
some of the burdens and limitations associ-
ated with dialysis, suggests a study in the 
Canadian Medical Association Journal.
The researchers performed a “discrete 
choice” experiment including 105 adult 
patients with stage 3 to 5 kidney disease at 
Australian renal clinics. The study looked 
at how various treatment characteristics af-
fected patients’ preferences for dialysis ver-
sus conservative care for progressive kidney 
disease. Variables included life expectancy, 
number of visits to the hospital per week, 
ability to travel, time spent undergoing di-
alysis, and other factors.
Patients were more likely to opt for 
dialysis if it increased their average life 
expectancy: odds ratio (OR) 1.84. Other 
factors affecting the preference for dialysis 
were the availability of dialysis during the 
evening as well as during daytime hours, 
OR 8.95; and the availability of subsidized 
transportation, OR 1.55. By contrast, pa-
tients were less likely to choose dialysis if it 
involved more hospital visits, OR 0.70; or 
if it placed more limits on their ability to 
travel, OR 0.47.
Patients would accept a 7-month reduc-
tion in life expectancy to avoid one extra 
hospital visit per week, and a 15-month re-
duction to decrease their travel restrictions. 
Patient age was not a significant influenc-
ing factor.
The results suggest that, even if dialy-
sis means longer survival, many patients 
with ESRD would prefer conservative care 
under certain circumstances. Patients are 
“willing to trade considerable life expect-
ancy to reduce the burdens and restrictions 
of dialysis,” the researchers write. They call 
for further study of decision making in 
older patients with ESRD, and of patient 
preferences regarding the type and location 
of dialysis [Morton RL, et al. Factors influ-
encing patient choice of dialysis versus con-
servative care to treated end-stage kidney 
disease. CMAJ 2012; 184:E277–E283]. 
For living-related donor kidney recipients, 
induction therapy with autologous mes-
enchymal stem cells (MSCs) can improve 
transplant outcomes, reports a study in the 
Journal of the American Medical Association.
The trial included 159 patients who 
were scheduled for living-related donor 
kidney transplantation from an ABO-
compatible, cross match–negative donor. 
In a 2:1 ratio, patients were randomly 
assigned to induction therapy with mar-
row-derived autologous MSCs or anti–
interleukin-2 antibody (basiliximab). 







centration of 1 to 2 x 106/kg at the time 
of kidney reperfusion, repeated at 2 weeks. 
All patients also received calcineurin in-
hibitors (CNIs); one-half of the MSC 
group received CNIs at 80 percent of the 
standard dose.
At 13 and 30 months, there were no 
significant differences in patient or graft 
survival. The 6-month rates of biopsy-
confirmed graft rejection were lower in 
patients receiving autologous MSCs: 7.5 
percent with standard-dose CNI and 7.7 
percent with low-dose CNI, compared 
with 21.6 percent in the basiliximab group. 
Induction therapy with MSCs also led to 
faster recovery of renal function during the 
first month after transplant in comparison 
with control individuals: mean difference 
6.2–10.0 mL/min per 1.73 m2. At 1 year, 
patients in the MSC groups had a signifi-
cantly lower rate of opportunistic infec-
tions: hazard ratio 0.42.
Autologous MSCs are a possible alter-
native to induction therapy with anti–in-
terleukin-2 antibody, with the potential 
to lower rejection risk. This open-label 
trial finds several advantages of MSC in-
duction therapy, including a lower acute 
rejection rate, more rapid return of kid-
ney function, and a lower rate of oppor-
tunistic infections. Long-term follow-up 
studies are planned [Tan J, et al. Induc-
tion therapy with autologous mesenchy-
mal stem cells in living-related kidney 
transplants: a randomized controlled 
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VOTRIENT (pazopanib) tablets 
The following is a brief summary only; see full prescribing information for 
complete product information.
WARNING: HEPATOTOXICITY
Severe and fatal hepatotoxicity has been observed in clinical studies. 
Monitor hepatic function and interrupt, reduce, or discontinue dosing  
as recommended. [See Warnings and Precautions (5.1).]
1 INDICATIONS AND USAGE 
VOTRIENT® is indicated for the treatment of patients with advanced renal cell 
carcinoma (RCC).
2 DOSAGE AND ADMINISTRATION 
2.1 Recommended Dosing: The recommended dose of VOTRIENT is  
800 mg orally once daily without food (at least 1 hour before or 2 hours after 
a meal) [see Clinical Pharmacology (12.3) of full prescribing information]. The 
dose of VOTRIENT should not exceed 800 mg. Do not crush tablets due to the 
potential for increased rate of absorption which may affect systemic exposure. 
[See Clinical Pharmacology (12.3) of full prescribing information.] If a dose is 
missed, it should not be taken if it is less than 12 hours until the next dose.  
2.2 Dose Modification Guidelines: Initial dose reduction should be 400 mg, 
and additional dose decrease or increase should be in 200 mg steps based on 
individual tolerability. The dose of VOTRIENT should not exceed 800 mg.  
Hepatic Impairment: No dose adjustment is required in patients with mild 
hepatic impairment. In patients with moderate hepatic impairment, alternatives 
to VOTRIENT should be considered. If VOTRIENT is used in patients with 
moderate hepatic impairment, the dose should be reduced to 200 mg per day. 
VOTRIENT is not recommended in patients with severe hepatic impairment. 
[See Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) of 
full prescribing information.] Concomitant Strong CYP3A4 Inhibitors: The 
concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, 
clarithromycin) may increase pazopanib concentrations and should be avoided. 
If coadministration of a strong CYP3A4 inhibitor is warranted, reduce the dose 
of VOTRIENT to 400 mg. Further dose reductions may be needed if adverse 
effects occur during therapy. This dose is predicted to adjust the pazopanib  
AUC to the range observed without inhibitors. However, there are no clinical 
data with this dose adjustment in patients receiving strong CYP3A4 inhibitors.  
[See Drug Interactions (7.1).] Concomitant Strong CYP3A4 Inducer: The 
concomitant use of strong CYP3A4 inducers (e.g., rifampin) may decrease 
pazopanib concentrations and should be avoided. VOTRIENT should not be  
used in patients who can not avoid chronic use of strong CYP3A4 inducers.  
[See Drug Interactions (7.1).]
4 CONTRAINDICATIONS 
None.
5 WARNINGS AND PRECAUTIONS 
5.1 Hepatic Effects: In clinical trials with VOTRIENT, hepatotoxicity, manifested 
as increases in serum transaminases (ALT, AST) and bilirubin, was observed 
[see Adverse Reactions (6.1)]. This hepatotoxicity can be severe and fatal. 
Transaminase elevations occur early in the course of treatment (92.5% of all 
transaminase elevations of any grade occurred in the first 18 weeks). Across all 
monotherapy studies with VOTRIENT, ALT >3 X upper limit of normal (ULN) was 
reported in 138/977 (14%) and ALT >8 X ULN was reported in 40/977 (4%) of 
patients who received VOTRIENT. Concurrent elevations in ALT >3 X ULN and 
bilirubin >2 X ULN regardless of alkaline phosphatase levels were detected in 
13/977 (1%) of patients. Four of the 13 patients had no other explanation for these 
elevations. Two of 977 (0.2%) patients died with disease progression and hepatic 
failure. Monitor serum liver tests before initiation of treatment with VOTRIENT 
and at least once every 4 weeks for at least the first 4 months of treatment or as 
clinically indicated. Periodic monitoring should then continue after this time 
period. Patients with isolated ALT elevations between 3 X ULN and 8 X ULN may 
be continued on VOTRIENT with weekly monitoring of liver function until ALT 
return to Grade 1 or baseline. Patients with isolated ALT elevations of >8 X ULN 
should have VOTRIENT interrupted until they return to Grade 1 or baseline. If the 
potential benefit for reinitiating treatment with VOTRIENT is considered to 
outweigh the risk for hepatotoxicity, then reintroduce VOTRIENT at a reduced 
dose of no more than 400 mg once daily and measure serum liver tests weekly 
for 8 weeks [see Dosage and Administration (2.2)]. Following reintroduction of 
VOTRIENT, if ALT elevations >3 X ULN recur, then VOTRIENT should be 
permanently discontinued. If ALT elevations >3 X ULN occur concurrently with 
bilirubin elevations >2 X ULN, VOTRIENT should be permanently discontinued. 
Patients should be monitored until resolution. VOTRIENT is a UGT1A1 inhibitor. 
Mild, indirect (unconjugated) hyperbilirubinemia may occur in patients with 
Gilbert’s syndrome [see Clinical Pharmacology (12.5) of full prescribing 
information]. Patients with only a mild indirect hyperbilirubinemia, known 
Gilbert’s syndrome, and elevation in ALT >3 X ULN should be managed as per 
the recommendations outlined for isolated ALT elevations. Concomitant use of 
VOTRIENT and simvastatin increases the risk of ALT elevations and should be 
undertaken with caution and close monitoring [see Drug Interactions (7.3)]. 
Insufficient data are available to assess the risk of concomitant administration 
of alternative statins and VOTRIENT. In patients with pre-existing moderate 
hepatic impairment, the starting dose of VOTRIENT should be reduced or 
alternatives to VOTRIENT should be considered. Treatment with VOTRIENT is not 
recommended in patients with pre-existing severe hepatic impairment, defined 
as total bilirubin >3 X ULN with any level of ALT. [See Dosage and Administration 
(2.2), Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) of full 
prescribing information.] 5.2 QT Prolongation and Torsades de Pointes: In 
clinical RCC studies of VOTRIENT, QT prolongation (≥500 msec) was identified 
on routine electrocardiogram monitoring in 11/558 (<2%) of patients. Torsades 
de pointes occurred in 2/977 (<1%) of patients who received VOTRIENT in the 
monotherapy studies. In the randomized clinical trial, 3 of the 290 patients 
receiving VOTRIENT had post-baseline values between 500 to 549 msec. None 
of the 145 patients receiving placebo had post-baseline QTc values ≥500 msec. 
VOTRIENT should be used with caution in patients with a history of QT interval 
prolongation, in patients taking antiarrhythmics or other medications that may 
prolong QT interval, and those with relevant pre-existing cardiac disease. When 
using VOTRIENT, baseline and periodic monitoring of electrocardiograms and 
maintenance of electrolytes (e.g., calcium, magnesium, potassium) within the 
normal range should be performed. 5.3 Hemorrhagic Events: In clinical RCC 
studies of VOTRIENT, hemorrhagic events have been reported [all Grades (16%) 
and Grades 3 to 5 (2%)]. Fatal hemorrhage has occurred in 5/586 (0.9%)  
[see Adverse Reactions (6.1)]. VOTRIENT has not been studied in patients who 
have a history of hemoptysis, cerebral, or clinically significant gastrointestinal 
hemorrhage in the past 6 months and should not be used in those patients.  
5.4 Arterial Thrombotic Events: In clinical RCC studies of VOTRIENT, 
myocardial infarction, angina, ischemic stroke, and transient ischemic attack 
[all Grades (3%) and Grades 3 to 5 (2%)] were observed. Fatal events have been 
observed in 2/586 (0.3%). In the randomized study, these events were observed 
more frequently with VOTRIENT compared to placebo [see Adverse Reactions 
(6.1)]. VOTRIENT should be used with caution in patients who are at increased 
risk for these events or who have had a history of these events. VOTRIENT has 
not been studied in patients who have had an event within the previous 6 
months and should not be used in those patients. 5.5 Gastrointestinal 
Perforation and Fistula: In clinical RCC studies of VOTRIENT, gastrointestinal 
perforation or fistula has been reported in 5 patients (0.9%). Fatal perforation 
events have occurred in 2/586 (0.3%). Monitor for symptoms of gastrointestinal 
perforation or fistula. 5.6 Hypertension : In clinical studies, events of 
hypertension including hypertensive crisis have occurred. Blood pressure  
should be well-controlled prior to initiating VOTRIENT. Patients should be 
monitored for hypertension and treated as needed with anti-hypertensive 
therapy. Hypertension (systolic blood pressure ≥150 or diastolic blood pressure 
≥100 mm Hg) was observed in 47% of patients with RCC treated with 
VOTRIENT. Hypertension occurs early in the course of treatment (39% of  
cases occurred by Day 9 and 88% of cases occurred in the first 18 weeks).  
[See Adverse Reactions (6.1).] In the case of persistent hypertension despite 
anti-hypertensive therapy, the dose of VOTRIENT may be reduced [see Dosage 
and Administration (2.2)]. VOTRIENT should be discontinued if there is evidence 
of hypertensive crisis or if hypertension is severe and persistent despite 
anti-hypertensive therapy and dose reduction of VOTRIENT. 5.7 Wound 
Healing: No formal studies on the effect of VOTRIENT on wound healing have 
been conducted. Since vascular endothelial growth factor receptor (VEGFR) 
inhibitors such as pazopanib may impair wound healing, treatment with 
VOTRIENT should be stopped at least 7 days prior to scheduled surgery.  
The decision to resume VOTRIENT after surgery should be based on clinical 
judgment of adequate wound healing. VOTRIENT should be discontinued in 
patients with wound dehiscence. 5.8 Hypothyroidism: In clinical RCC studies  
of VOTRIENT, hypothyroidism reported as an adverse reaction in 26/586 (4%) 
[see Adverse Reactions (6.1)]. Proactive monitoring of thyroid function tests is 
recommended. 5.9 Proteinuria: In clinical RCC studies with VOTRIENT, 
proteinuria has been reported in 44/586 (8%) [Grade 3, 5/586 (<1%) and Grade 
4, 1/586 (<1%)] [see Adverse Reactions (6.1)]. Baseline and periodic urinalysis 
during treatment is recommended. VOTRIENT should be discontinued if the 
patient develops Grade 4 proteinuria. 5.10 Pregnancy: VOTRIENT can cause 
fetal harm when administered to a pregnant woman. Based on its mechanism  
of action, VOTRIENT is expected to result in adverse reproductive effects. In 
pre-clinical studies in rats and rabbits, pazopanib was teratogenic, embryotoxic, 
fetotoxic, and abortifacient. There are no adequate and well-controlled studies 
of VOTRIENT in pregnant women. If this drug is used during pregnancy, or if the 
patient becomes pregnant while taking this drug, the patient should be apprised 
of the potential hazard to the fetus. Women of childbearing potential should be 
advised to avoid becoming pregnant while taking VOTRIENT. [See Use in 
Specific Populations (8.1).]
6 ADVERSE REACTIONS 
6.1 Clinical Trials Experience: Because clinical trials are conducted under 
widely varying conditions, adverse reaction rates observed in the clinical trials 
of a drug cannot be directly compared to rates in the clinical trials of another 
drug and may not reflect the rates observed in practice. Potentially serious 
adverse reactions with VOTRIENT included hepatotoxicity, QT prolongation 
and torsades de pointes, hemorrhagic events, arterial thrombotic events, 
gastrointestinal perforation and fistula, and hypertensive crisis [see Warnings 
and Precautions (5.1-5.5)]. The safety of VOTRIENT has been evaluated in 977 
patients in the monotherapy studies which included 586 patients with RCC 
at the time of NDA submission. With a median duration of treatment of 7.4 
months (range 0.1 to 27.6), the most commonly observed adverse reactions 
(≥20%) in the 586 patients were diarrhea, hypertension, hair color change, 
nausea, fatigue, anorexia, and vomiting. The data described below reflect 
the safety profile of VOTRIENT in 290 RCC patients who participated in a 
randomized, double-blind, placebo-controlled study [see Clinical Studies (14) of 
full prescribing information]. The median duration of treatment was 7.4 months 
(range 0 to 23) for patients who received VOTRIENT and 3.8 months (range 0 
to 22) for the placebo arm. Forty-two percent (42%) of patients on VOTRIENT 
required a dose interruption. Thirty-six percent (36%) of patients on VOTRIENT 
were dose reduced. Table 1 presents the most common adverse reactions 
occurring in ≥10% of patients who received VOTRIENT.






Gradesa Grade 3 Grade 4
All 
Gradesa Grade 3 Grade 4
% % % % % %
Diarrhea 52 3 <1 9 <1 0
Hypertension 40 4 0 10 <1 0
Hair color changes 38 <1 0 3 0 0
Nausea 26 <1 0 9 0 0
Anorexia 22 2 0 10 <1 0
Vomiting 21 2 <1 8 2 0
Fatigue 19 2 0 8 1 1
Asthenia 14 3 0 8 0 0
Abdominal pain 11 2 0 1 0 0
Headache 10 0 0 5 0 0
a  National Cancer Institute Common Terminology Criteria for Adverse Events, 
version 3.
Other adverse reactions observed more commonly in patients treated with 
VOTRIENT than placebo and that occurred in <10% (any grade) were alopecia 
(8% versus <1%), chest pain (5% versus 1%), dysgeusia (altered taste) (8% 
versus <1%), dyspepsia (5% versus <1%), facial edema (1% versus 0%), 
palmar-plantar erythrodysesthesia (hand-foot syndrome) (6% versus <1%), 
proteinuria (9% versus 0%), rash (8% versus 3%), skin depigmentation (3% 
versus 0%), and weight decreased (9% versus 3%).
Table 2 presents the most common laboratory abnormalities occurring in >10% 
of patients who received VOTRIENT and more commonly (≥5%) in patients who 
received VOTRIENT versus placebo.
Table 2. Selected Laboratory Abnormalities Occurring in >10% of Patients 
who Received VOTRIENT and More Commonly (≥5%) in Patients who 








Gradesa Grade 3 Grade 4
All 
Gradesa Grade 3 Grade 4
% % % % % %
 Hematologic
Leukopenia 37 0 0 6 0 0
Neutropenia 34 1 <1 6 0 0
Thrombocytopenia 32 <1 <1 5 0 <1
Lymphocytopenia 31 4 <1 24 1 0
 Chemistry
ALT increased 53 10 2 22 1 0
AST increased 53 7 <1 19 <1 0
Glucose  
increased 41 <1 0 33 1 0
Total bilirubin  
increased 36 3 <1 10 1 <1
Phosphorus  
decreased 34 4 0 11 0 0
Sodium  
decreased 31 4 1 24 4 0
Magnesium  
decreased 26 <1 1 14 0 0
Glucose  
decreased 17 0 <1 3 0 0
a  National Cancer Institute Common Terminology Criteria for Adverse Events, 
version 3.
Hepatic Toxicity: In a controlled clinical study with VOTRIENT for the treatment 
of RCC, ALT >3 X ULN was reported in 18% and 3% of the VOTRIENT and 
placebo groups, respectively. ALT >10 X ULN was reported in 4% of patients 
who received VOTRIENT and in <1% of patients who received placebo. 
Concurrent elevation in ALT >3 X ULN and bilirubin >2 X ULN in the absence of 
significant alkaline phosphatase >3 X ULN occurred in 5/290 (2%) of patients on 
VOTRIENT and 2/145 (1%) on placebo. [See Dosage and Administration (2.2) of 
full prescribing information and Warnings and Precautions (5.1).] Hypertension: 
In a controlled clinical study with VOTRIENT for the treatment of RCC, 115/290 
patients (40%) receiving VOTRIENT compared with 15/145 patients (10%) 
on placebo experienced hypertension. Grade 3 hypertension was reported in 
13/290 patients (4%) receiving VOTRIENT compared with 1/145 patients (<1%) 
on placebo. The majority of cases of hypertension were manageable with anti-
hypertensive agents or dose reductions with 2/290 patients (<1%) permanently 
discontinuing treatment with VOTRIENT because of hypertension. VOTRIENT 
has been associated with hypertensive crisis in patients with various cancer 
types including RCC. In the overall safety population for RCC (N = 586), one 
patient had hypertensive crisis on VOTRIENT. [See Warnings and Precautions 
(5.6).] QT Prolongation and Torsades de Pointes: In a controlled clinical 
study with VOTRIENT, QT prolongation (≥500 msec) was identified on routine 
electrocardiogram monitoring in 3/290 (1%) of patients treated with VOTRIENT 
compared with no patients on placebo. Torsades de pointes was reported in 
2/586 (<1%) patients treated with VOTRIENT in the RCC studies. [See Warnings 
and Precautions (5.2).] Arterial Thrombotic Events: In a controlled clinical 
study with VOTRIENT, the incidences of arterial thrombotic events such as 
myocardial infarction/ischemia [5/290 (2%)], cerebral vascular accident [1/290 
(<1%)], and transient ischemic attack [4/290 (1%)] were higher in patients 
treated with VOTRIENT compared to the placebo arm (0/145 for each event). 
[See Warnings and Precautions (5.4).] Hemorrhagic Events: In a controlled 
clinical study with VOTRIENT, 37/290 patients (13%) treated with VOTRIENT 
and 7/145 patients (5%) on placebo experienced at least 1 hemorrhagic event. 
The most common hemorrhagic events in the patients treated with VOTRIENT 
were hematuria (4%), epistaxis (2%), hemoptysis (2%), and rectal hemorrhage 
(1%). Nine (9/37) patients treated with VOTRIENT who had hemorrhagic 
events experienced serious events including pulmonary, gastrointestinal, and 
genitourinary hemorrhage. Four (4/290) (1%) patients treated with VOTRIENT 
died from hemorrhage compared with no (0/145) (0%) patients on placebo. 
[See Warnings and Precautions (5.3).] In the overall safety population in RCC 
(N = 586), cerebral/intracranial hemorrhage was observed in 2/586 (<1%) 
patients treated with VOTRIENT. Hypothyroidism: In a controlled clinical study 
with VOTRIENT, more patients had a shift from thyroid stimulating hormone 
(TSH) within the normal range at baseline to above the normal range at any 
post-baseline visit in VOTRIENT compared with the placebo arm (27% compared 
with 5%, respectively). Hypothyroidism was reported as an adverse reaction in 
19 patients (7%) treated with VOTRIENT and no patients (0%) in the placebo arm. 
[See Warnings and Precautions (5.8).] Diarrhea: Diarrhea occurred frequently 
and was predominantly mild to moderate in severity. Patients should be advised 
how to manage mild diarrhea and to notify their healthcare provider if moderate 
to severe diarrhea occurs so appropriate management can be implemented to 
minimize its impact. Proteinuria: In the controlled clinical study with VOTRIENT, 
proteinuria has been reported as an adverse reaction in 27 patients (9%) treated 
with VOTRIENT. In 2 patients, proteinuria led to discontinuation of treatment with 
VOTRIENT. [See Warnings and Precautions (5.9).] Lipase Elevations: In a single-
arm clinical study, increases in lipase values were observed for 48/181 patients 
(27%). Elevations in lipase as an adverse reaction were reported for 10 patients 
(4%) and were Grade 3 for 6 patients and Grade 4 for 1 patient. In clinical RCC 
studies of VOTRIENT, clinical pancreatitis was observed in 4/586 patients (<1%). 
Cardiac Dysfunction: Pazopanib has been associated with cardiac dysfunction 
(such as a decrease in ejection fraction and congestive heart failure) in patients 
with various cancer types, including RCC. In the overall safety population for RCC 
(N = 586), cardiac dysfunction was observed in 4/586 patients (<1%).
7 DRUG INTERACTIONS 
7.1 Drugs That Inhibit or Induce Cytochrome P450 3A4 Enzymes: In vitro 
studies suggested that the oxidative metabolism of pazopanib in human liver 
microsomes is mediated primarily by CYP3A4, with minor contributions from 
CYP1A2 and CYP2C8. Therefore, inhibitors and inducers of CYP3A4 may alter 
the metabolism of pazopanib. CYP3A4 Inhibitors: Coadministration of pazopanib 
with strong inhibitors of CYP3A4 (e.g., ketoconazole, ritonavir, clarithromycin) 
may increase pazopanib concentrations. A dose reduction for VOTRIENT should 
be considered when it must be coadministered with strong CYP3A4 inhibitors 
[see Dosage and Administration (2.2)]. Grapefruit juice should be avoided 
as it inhibits CYP3A4 activity and may also increase plasma concentrations 
of pazopanib. CYP3A4 Inducers: CYP3A4 inducers such as rifampin may 
decrease plasma pazopanib concentrations. VOTRIENT should not be used if 
chronic use of strong CYP3A4 inducers can not be avoided [see Dosage and 
Administration (2.2)]. 7.2 Effects of Pazopanib on CYP Substrates: Results 
from drug-drug interaction studies conducted in cancer patients suggest that 
pazopanib is a weak inhibitor of CYP3A4, CYP2C8, and CYP2D6 in vivo, but 
had no effect on CYP1A2, CYP2C9, or CYP2C19 [see Clinical Pharmacology 
(12.3) of full prescribing information]. Concomitant use of VOTRIENT with 
agents with narrow therapeutic windows that are metabolized by CYP3A4, 
CYP2D6, or CYP2C8 is not recommended. Coadministration may result in 
inhibition of the metabolism of these products and create the potential for 
serious adverse events. [See Clinical Pharmacology (12.3) of full prescribing 
information.] 7.3 Effect of Concomitant use of VOTRIENT and Simvastatin: 
Concomitant use of VOTRIENT and simvastatin increases the incidence of ALT 
elevations. Across monotherapy studies with VOTRIENT, ALT >3 X ULN was 
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Dipeptidyl peptidase-4 (DPP-4) inhibi-
tors are an effective alternative for second-
line therapy in patients with type 2 diabe-
tes, reports a meta-analysis in the British 
Medical Journal.
The analysis pooled data from 19 ran-
domized trials, including 7136 patients 
assigned to a DPP-4 inhibitor and 6745 
to other hypoglycemic treatments. The 
results showed a smaller decrease in gly-
cated hemoglobin (HbA1c) with DPP-
4 inhibitors compared with metformin 
alone, weighted mean difference 0.20; and 
a lesser decrease in body weight, weighted 
mean difference 1.50.
As second-line treatment to reduce 
HbA1c, DPP-4 inhibitors were less effec-
tive than glucagon-like peptide-1 (GLP-1) 
agonists and sulfonylureas but were similar 
to pioglitazone. The DPP-4 inhibitors led 
to more favorable changes in body weight 
compared with sulfonylureas or pioglita-
zone but not compared with GLP-1 ago-
nists.
Studies comparing DPP-4 inhibitors 
against metformin alone or with pioglita-
zone or against a GLP-1 agonist included 
few episodes of hypoglycemia. Most stud-
ies comparing a DPP-4 inhibitor plus a 
sulfonylurea against metformin showed 
a higher risk of hypoglycemia in patients 
taking sulfonylureas. The DDP-4 inhibi-
tors had a lower rate of serious adverse 
events than did pioglitazone. They did not 
increase the risks of nasopharyngitis, up-
per respiratory tract infection, or urinary 
tract infection.
The updated review and meta-analysis 
may help to clarify the clinical role of the 
DPP-4 inhibitors, a newer class of oral 
hypoglycemic drugs. These medications 
appear to be effective in lowering HbA1c 
in patients with type 2 diabetes who do 
not respond to metformin alone. Further 
study is needed to assess their cost effec-
tiveness and long-term safety outcomes 
[Karagiannis T, et al. Dipeptidyl pepti-
dase-4 inhibitors for treatment of type 2 
diabetes mellitus in the clinical setting: 
systematic review and meta-analysis. BMJ 
2012; 344:e1369].  
At least 10 percent of children with acute 
kidney injury (AKI) in a children’s hospital 
intensive care unit (ICU) will experience 
chronic kidney disease (CKD) within the 
next few years, according to a report in the 
American Journal of Kidney Disease.
The researchers analyzed prospective 
follow-up data on 126 children with AKI 
admitted to the pediatric ICU in a Canadi-
an children’s hospital from 2006 to 2008. 
(Another 173 children were lost to follow-
up.) One-fourth of the patients were new-
borns; in more than half, AKI was associ-
ated with open-heart surgery.
As defined by AKI Network criteria, 
severity was stage 1 in 35 percent of chil-
dren, stage 2 in 37 percent, and stage 3 in 
28 percent. At 1–3 years of follow-up, the 
rates of CKD—defined as the presence of 
albuminuria and/or glomerular filtration 
rate (GFR) less than 60 mL/min/1.73 
m2—was assessed.
At follow-up, the criteria for CKD were 
met in 10.3 percent of children who had 
stage 1 AKI, 10.6 percent with stage 2 
AKI, and 17.1 percent with stage 3 AKI. 
Another 46.8 percent of children were 
considered at risk of CKD on the basis of 
mildly to moderately reduced kidney func-
tion (GFR 60–90 mL/min/1.73 m2), high 
blood pressure, or hyperfiltration (GFR 
60–90 mL/min/1.73 m2).
 Of these tertiary care pediatric 
ICU patients with AKI, more than 10 per-
cent go on to experience CKD. Overall, 
most of these children either have CKD 
or are considered at risk for the develop-
ment of CKD at follow-up. The authors 
believe that all children with AKI should 





ney damage [Mammen C, et al. Long-term 
risk of CKD in children surviving episodes 
of acute kidney injury in the intensive care 
unit: a prospective cohort study. Am J Kid-
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VOTRIENT (pazopanib) tablets 
The following is a brief summary only; see full prescribing information for 
complete product information.
WARNING: HEPATOTOXICITY
Severe and fatal hepatotoxicity has been observed in clinical studies. 
Monitor hepatic function and interrupt, reduce, or discontinue dosing  
as recommended. [See Warnings and Precautions (5.1).]
1 INDICATIONS AND USAGE 
VOTRIENT® is indicated for the treatment of patients with advanced renal cell 
carcinoma (RCC).
2 DOSAGE AND ADMINISTRATION 
2.1 Recommended Dosing: The recommended dose of VOTRIENT is  
800 mg orally once daily without food (at least 1 hour before or 2 hours after 
a meal) [see Clinical Pharmacology (12.3) of full prescribing information]. The 
dose of VOTRIENT should not exceed 800 mg. Do not crush tablets due to the 
potential for increased rate of absorption which may affect systemic exposure. 
[See Clinical Pharmacology (12.3) of full prescribing information.] If a dose is 
missed, it should not be taken if it is less than 12 hours until the next dose.  
2.2 Dose Modification Guidelines: Initial dose reduction should be 400 mg, 
and additional dose decrease or increase should be in 200 mg steps based on 
individual tolerability. The dose of VOTRIENT should not exceed 800 mg.  
Hepatic Impairment: No dose adjustment is required in patients with mild 
hepatic impairment. In patients with moderate hepatic impairment, alternatives 
to VOTRIENT should be considered. If VOTRIENT is used in patients with 
moderate hepatic impairment, the dose should be reduced to 200 mg per day. 
VOTRIENT is not recommended in patients with severe hepatic impairment. 
[See Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) of 
full prescribing information.] Concomitant Strong CYP3A4 Inhibitors: The 
concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, 
clarithromycin) may increase pazopanib concentrations and should be avoided. 
If coadministration of a strong CYP3A4 inhibitor is warranted, reduce the dose 
of VOTRIENT to 400 mg. Further dose reductions may be needed if adverse 
effects occur during therapy. This dose is predicted to adjust the pazopanib  
AUC to the range observed without inhibitors. However, there are no clinical 
data with this dose adjustment in patients receiving strong CYP3A4 inhibitors.  
[See Drug Interactions (7.1).] Concomitant Strong CYP3A4 Inducer: The 
concomitant use of strong CYP3A4 inducers (e.g., rifampin) may decrease 
pazopanib concentrations and should be avoided. VOTRIENT should not be  
used in patients who can not avoid chronic use of strong CYP3A4 inducers.  
[See Drug Interactions (7.1).]
4 CONTRAINDICATIONS 
None.
5 WARNINGS AND PRECAUTIONS 
5.1 Hepatic Effects: In clinical trials with VOTRIENT, hepatotoxicity, manifested 
as increases in serum transaminases (ALT, AST) and bilirubin, was observed 
[see Adverse Reactions (6.1)]. This hepatotoxicity can be severe and fatal. 
Transaminase elevations occur early in the course of treatment (92.5% of all 
transaminase elevations of any grade occurred in the first 18 weeks). Across all 
monotherapy studies with VOTRIENT, ALT >3 X upper limit of normal (ULN) was 
reported in 138/977 (14%) and ALT >8 X ULN was reported in 40/977 (4%) of 
patients who received VOTRIENT. Concurrent elevations in ALT >3 X ULN and 
bilirubin >2 X ULN regardless of alkaline phosphatase levels were detected in 
13/977 (1%) of patients. Four of the 13 patients had no other explanation for these 
elevations. Two of 977 (0.2%) patients died with disease progression and hepatic 
failure. Monitor serum liver tests before initiation of treatment with VOTRIENT 
and at least once every 4 weeks for at least the first 4 months of treatment or as 
clinically indicated. Periodic monitoring should then continue after this time 
period. Patients with isolated ALT elevations between 3 X ULN and 8 X ULN may 
be continued on VOTRIENT with weekly monitoring of liver function until ALT 
return to Grade 1 or baseline. Patients with isolated ALT elevations of >8 X ULN 
should have VOTRIENT interrupted until they return to Grade 1 or baseline. If the 
potential benefit for reinitiating treatment with VOTRIENT is considered to 
outweigh the risk for hepatotoxicity, then reintroduce VOTRIENT at a reduced 
dose of no more than 400 mg once daily and measure serum liver tests weekly 
for 8 weeks [see Dosage and Administration (2.2)]. Following reintroduction of 
VOTRIENT, if ALT elevations >3 X ULN recur, then VOTRIENT should be 
permanently discontinued. If ALT elevations >3 X ULN occur concurrently with 
bilirubin elevations >2 X ULN, VOTRIENT should be permanently discontinued. 
Patients should be monitored until resolution. VOTRIENT is a UGT1A1 inhibitor. 
Mild, indirect (unconjugated) hyperbilirubinemia may occur in patients with 
Gilbert’s syndrome [see Clinical Pharmacology (12.5) of full prescribing 
information]. Patients with only a mild indirect hyperbilirubinemia, known 
Gilbert’s syndrome, and elevation in ALT >3 X ULN should be managed as per 
the recommendations outlined for isolated ALT elevations. Concomitant use of 
VOTRIENT and simvastatin increases the risk of ALT elevations and should be 
undertaken with caution and close monitoring [see Drug Interactions (7.3)]. 
Insufficient data are available to assess the risk of concomitant administration 
of alternative statins and VOTRIENT. In patients with pre-existing moderate 
hepatic impairment, the starting dose of VOTRIENT should be reduced or 
alternatives to VOTRIENT should be considered. Treatment with VOTRIENT is not 
recommended in patients with pre-existing severe hepatic impairment, defined 
as total bilirubin >3 X ULN with any level of ALT. [See Dosage and Administration 
(2.2), Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) of full 
prescribing information.] 5.2 QT Prolongation and Torsades de Pointes: In 
clinical RCC studies of VOTRIENT, QT prolongation (≥500 msec) was identified 
on routine electrocardiogram monitoring in 11/558 (<2%) of patients. Torsades 
de pointes occurred in 2/977 (<1%) of patients who received VOTRIENT in the 
monotherapy studies. In the randomized clinical trial, 3 of the 290 patients 
receiving VOTRIENT had post-baseline values between 500 to 549 msec. None 
of the 145 patients receiving placebo had post-baseline QTc values ≥500 msec. 
VOTRIENT should be used with caution in patients with a history of QT interval 
prolongation, in patients taking antiarrhythmics or other medications that may 
prolong QT interval, and those with relevant pre-existing cardiac disease. When 
using VOTRIENT, baseline and periodic monitoring of electrocardiograms and 
maintenance of electrolytes (e.g., calcium, magnesium, potassium) within the 
normal range should be performed. 5.3 Hemorrhagic Events: In clinical RCC 
studies of VOTRIENT, hemorrhagic events have been reported [all Grades (16%) 
and Grades 3 to 5 (2%)]. Fatal hemorrhage has occurred in 5/586 (0.9%)  
[see Adverse Reactions (6.1)]. VOTRIENT has not been studied in patients who 
have a history of hemoptysis, cerebral, or clinically significant gastrointestinal 
hemorrhage in the past 6 months and should not be used in those patients.  
5.4 Arterial Thrombotic Events: In clinical RCC studies of VOTRIENT, 
myocardial infarction, angina, ischemic stroke, and transient ischemic attack 
[all Grades (3%) and Grades 3 to 5 (2%)] were observed. Fatal events have been 
observed in 2/586 (0.3%). In the randomized study, these events were observed 
more frequently with VOTRIENT compared to placebo [see Adverse Reactions 
(6.1)]. VOTRIENT should be used with caution in patients who are at increased 
risk for these events or who have had a history of these events. VOTRIENT has 
not been studied in patients who have had an event within the previous 6 
months and should not be used in those patients. 5.5 Gastrointestinal 
Perforation and Fistula: In clinical RCC studies of VOTRIENT, gastrointestinal 
perforation or fistula has been reported in 5 patients (0.9%). Fatal perforation 
events have occurred in 2/586 (0.3%). Monitor for symptoms of gastrointestinal 
perforation or fistula. 5.6 Hypertension : In clinical studies, events of 
hypertension including hypertensive crisis have occurred. Blood pressure  
should be well-controlled prior to initiating VOTRIENT. Patients should be 
monitored for hypertension and treated as needed with anti-hypertensive 
therapy. Hypertension (systolic blood pressure ≥150 or diastolic blood pressure 
≥100 mm Hg) was observed in 47% of patients with RCC treated with 
VOTRIENT. Hypertension occurs early in the course of treatment (39% of  
cases occurred by Day 9 and 88% of cases occurred in the first 18 weeks).  
[See Adverse Reactions (6.1).] In the case of persistent hypertension despite 
anti-hypertensive therapy, the dose of VOTRIENT may be reduced [see Dosage 
and Administration (2.2)]. VOTRIENT should be discontinued if there is evidence 
of hypertensive crisis or if hypertension is severe and persistent despite 
anti-hypertensive therapy and dose reduction of VOTRIENT. 5.7 Wound 
Healing: No formal studies on the effect of VOTRIENT on wound healing have 
been conducted. Since vascular endothelial growth factor receptor (VEGFR) 
inhibitors such as pazopanib may impair wound healing, treatment with 
VOTRIENT should be stopped at least 7 days prior to scheduled surgery.  
The decision to resume VOTRIENT after surgery should be based on clinical 
judgment of adequate wound healing. VOTRIENT should be discontinued in 
patients with wound dehiscence. 5.8 Hypothyroidism: In clinical RCC studies  
of VOTRIENT, hypothyroidism reported as an adverse reaction in 26/586 (4%) 
[see Adverse Reactions (6.1)]. Proactive monitoring of thyroid function tests is 
recommended. 5.9 Proteinuria: In clinical RCC studies with VOTRIENT, 
proteinuria has been reported in 44/586 (8%) [Grade 3, 5/586 (<1%) and Grade 
4, 1/586 (<1%)] [see Adverse Reactions (6.1)]. Baseline and periodic urinalysis 
during treatment is recommended. VOTRIENT should be discontinued if the 
patient develops Grade 4 proteinuria. 5.10 Pregnancy: VOTRIENT can cause 
fetal harm when administered to a pregnant woman. Based on its mechanism  
of action, VOTRIENT is expected to result in adverse reproductive effects. In 
pre-clinical studies in rats and rabbits, pazopanib was teratogenic, embryotoxic, 
fetotoxic, and abortifacient. There are no adequate and well-controlled studies 
of VOTRIENT in pregnant women. If this drug is used during pregnancy, or if the 
patient becomes pregnant while taking this drug, the patient should be apprised 
of the potential hazard to the fetus. Women of childbearing potential should be 
advised to avoid becoming pregnant while taking VOTRIENT. [See Use in 
Specific Populations (8.1).]
6 ADVERSE REACTIONS 
6.1 Clinical Trials Experience: Because clinical trials are conducted under 
widely varying conditions, adverse reaction rates observed in the clinical trials 
of a drug cannot be directly compared to rates in the clinical trials of another 
drug and may not reflect the rates observed in practice. Potentially serious 
adverse reactions with VOTRIENT included hepatotoxicity, QT prolongation 
and torsades de pointes, hemorrhagic events, arterial thrombotic events, 
gastrointestinal perforation and fistula, and hypertensive crisis [see Warnings 
and Precautions (5.1-5.5)]. The safety of VOTRIENT has been evaluated in 977 
patients in the monotherapy studies which included 586 patients with RCC 
at the time of NDA submission. With a median duration of treatment of 7.4 
months (range 0.1 to 27.6), the most commonly observed adverse reactions 
(≥20%) in the 586 patients were diarrhea, hypertension, hair color change, 
nausea, fatigue, anorexia, and vomiting. The data described below reflect 
the safety profile of VOTRIENT in 290 RCC patients who participated in a 
randomized, double-blind, placebo-controlled study [see Clinical Studies (14) of 
full prescribing information]. The median duration of treatment was 7.4 months 
(range 0 to 23) for patients who received VOTRIENT and 3.8 months (range 0 
to 22) for the placebo arm. Forty-two percent (42%) of patients on VOTRIENT 
required a dose interruption. Thirty-six percent (36%) of patients on VOTRIENT 
were dose reduced. Table 1 presents the most common adverse reactions 
occurring in ≥10% of patients who received VOTRIENT.






Gradesa Grade 3 Grade 4
All 
Gradesa Grade 3 Grade 4
% % % % % %
Diarrhea 52 3 <1 9 <1 0
Hypertension 40 4 0 10 <1 0
Hair color changes 38 <1 0 3 0 0
Nausea 26 <1 0 9 0 0
Anorexia 22 2 0 10 <1 0
Vomiting 21 2 <1 8 2 0
Fatigue 19 2 0 8 1 1
Asthenia 14 3 0 8 0 0
Abdominal pain 11 2 0 1 0 0
Headache 10 0 0 5 0 0
a  National Cancer Institute Common Terminology Criteria for Adverse Events, 
version 3.
Other adverse reactions observed more commonly in patients treated with 
VOTRIENT than placebo and that occurred in <10% (any grade) were alopecia 
(8% versus <1%), chest pain (5% versus 1%), dysgeusia (altered taste) (8% 
versus <1%), dyspepsia (5% versus <1%), facial edema (1% versus 0%), 
palmar-plantar erythrodysesthesia (hand-foot syndrome) (6% versus <1%), 
proteinuria (9% versus 0%), rash (8% versus 3%), skin depigmentation (3% 
versus 0%), and weight decreased (9% versus 3%).
Table 2 presents the most common laboratory abnormalities occurring in >10% 
of patients who received VOTRIENT and more commonly (≥5%) in patients who 
received VOTRIENT versus placebo.
Table 2. Selected Laboratory Abnormalities Occurring in >10% of Patients 
who Received VOTRIENT and More Commonly (≥5%) in Patients who 








Gradesa Grade 3 Grade 4
All 
Gradesa Grade 3 Grade 4
% % % % % %
 Hematologic
Leukopenia 37 0 0 6 0 0
Neutropenia 34 1 <1 6 0 0
Thrombocytopenia 32 <1 <1 5 0 <1
Lymphocytopenia 31 4 <1 24 1 0
 Chemistry
ALT increased 53 10 2 22 1 0
AST increased 53 7 <1 19 <1 0
Glucose  
increased 41 <1 0 33 1 0
Total bilirubin  
increased 36 3 <1 10 1 <1
Phosphorus  
decreased 34 4 0 11 0 0
Sodium  
decreased 31 4 1 24 4 0
Magnesium  
decreased 26 <1 1 14 0 0
Glucose  
decreased 17 0 <1 3 0 0
a  National Cancer Institute Common Terminology Criteria for Adverse Events, 
version 3.
Hepatic Toxicity: In a controlled clinical study with VOTRIENT for the treatment 
of RCC, ALT >3 X ULN was reported in 18% and 3% of the VOTRIENT and 
placebo groups, respectively. ALT >10 X ULN was reported in 4% of patients 
who received VOTRIENT and in <1% of patients who received placebo. 
Concurrent elevation in ALT >3 X ULN and bilirubin >2 X ULN in the absence of 
significant alkaline phosphatase >3 X ULN occurred in 5/290 (2%) of patients on 
VOTRIENT and 2/145 (1%) on placebo. [See Dosage and Administration (2.2) of 
full prescribing information and Warnings and Precautions (5.1).] Hypertension: 
In a controlled clinical study with VOTRIENT for the treatment of RCC, 115/290 
patients (40%) receiving VOTRIENT compared with 15/145 patients (10%) 
on placebo experienced hypertension. Grade 3 hypertension was reported in 
13/290 patients (4%) receiving VOTRIENT compared with 1/145 patients (<1%) 
on placebo. The majority of cases of hypertension were manageable with anti-
hypertensive agents or dose reductions with 2/290 patients (<1%) permanently 
discontinuing treatment with VOTRIENT because of hypertension. VOTRIENT 
has been associated with hypertensive crisis in patients with various cancer 
types including RCC. In the overall safety population for RCC (N = 586), one 
patient had hypertensive crisis on VOTRIENT. [See Warnings and Precautions 
(5.6).] QT Prolongation and Torsades de Pointes: In a controlled clinical 
study with VOTRIENT, QT prolongation (≥500 msec) was identified on routine 
electrocardiogram monitoring in 3/290 (1%) of patients treated with VOTRIENT 
compared with no patients on placebo. Torsades de pointes was reported in 
2/586 (<1%) patients treated with VOTRIENT in the RCC studies. [See Warnings 
and Precautions (5.2).] Arterial Thrombotic Events: In a controlled clinical 
study with VOTRIENT, the incidences of arterial thrombotic events such as 
myocardial infarction/ischemia [5/290 (2%)], cerebral vascular accident [1/290 
(<1%)], and transient ischemic attack [4/290 (1%)] were higher in patients 
treated with VOTRIENT compared to the placebo arm (0/145 for each event). 
[See Warnings and Precautions (5.4).] Hemorrhagic Events: In a controlled 
clinical study with VOTRIENT, 37/290 patients (13%) treated with VOTRIENT 
and 7/145 patients (5%) on placebo experienced at least 1 hemorrhagic event. 
The most common hemorrhagic events in the patients treated with VOTRIENT 
were hematuria (4%), epistaxis (2%), hemoptysis (2%), and rectal hemorrhage 
(1%). Nine (9/37) patients treated with VOTRIENT who had hemorrhagic 
events experienced serious events including pulmonary, gastrointestinal, and 
genitourinary hemorrhage. Four (4/290) (1%) patients treated with VOTRIENT 
died from hemorrhage compared with no (0/145) (0%) patients on placebo. 
[See Warnings and Precautions (5.3).] In the overall safety population in RCC 
(N = 586), cerebral/intracranial hemorrhage was observed in 2/586 (<1%) 
patients treated with VOTRIENT. Hypothyroidism: In a controlled clinical study 
with VOTRIENT, more patients had a shift from thyroid stimulating hormone 
(TSH) within the normal range at baseline to above the normal range at any 
post-baseline visit in VOTRIENT compared with the placebo arm (27% compared 
with 5%, respectively). Hypothyroidism was reported as an adverse reaction in 
19 patients (7%) treated with VOTRIENT and no patients (0%) in the placebo arm. 
[See Warnings and Precautions (5.8).] Diarrhea: Diarrhea occurred frequently 
and was predominantly mild to moderate in severity. Patients should be advised 
how to manage mild diarrhea and to notify their healthcare provider if moderate 
to severe diarrhea occurs so appropriate management can be implemented to 
minimize its impact. Proteinuria: In the controlled clinical study with VOTRIENT, 
proteinuria has been reported as an adverse reaction in 27 patients (9%) treated 
with VOTRIENT. In 2 patients, proteinuria led to discontinuation of treatment with 
VOTRIENT. [See Warnings and Precautions (5.9).] Lipase Elevations: In a single-
arm clinical study, increases in lipase values were observed for 48/181 patients 
(27%). Elevations in lipase as an adverse reaction were reported for 10 patients 
(4%) and were Grade 3 for 6 patients and Grade 4 for 1 patient. In clinical RCC 
studies of VOTRIENT, clinical pancreatitis was observed in 4/586 patients (<1%). 
Cardiac Dysfunction: Pazopanib has been associated with cardiac dysfunction 
(such as a decrease in ejection fraction and congestive heart failure) in patients 
with various cancer types, including RCC. In the overall safety population for RCC 
(N = 586), cardiac dysfunction was observed in 4/586 patients (<1%).
7 DRUG INTERACTIONS 
7.1 Drugs That Inhibit or Induce Cytochrome P450 3A4 Enzymes: In vitro 
studies suggested that the oxidative metabolism of pazopanib in human liver 
microsomes is mediated primarily by CYP3A4, with minor contributions from 
CYP1A2 and CYP2C8. Therefore, inhibitors and inducers of CYP3A4 may alter 
the metabolism of pazopanib. CYP3A4 Inhibitors: Coadministration of pazopanib 
with strong inhibitors of CYP3A4 (e.g., ketoconazole, ritonavir, clarithromycin) 
may increase pazopanib concentrations. A dose reduction for VOTRIENT should 
be considered when it must be coadministered with strong CYP3A4 inhibitors 
[see Dosage and Administration (2.2)]. Grapefruit juice should be avoided 
as it inhibits CYP3A4 activity and may also increase plasma concentrations 
of pazopanib. CYP3A4 Inducers: CYP3A4 inducers such as rifampin may 
decrease plasma pazopanib concentrations. VOTRIENT should not be used if 
chronic use of strong CYP3A4 inducers can not be avoided [see Dosage and 
Administration (2.2)]. 7.2 Effects of Pazopanib on CYP Substrates: Results 
from drug-drug interaction studies conducted in cancer patients suggest that 
pazopanib is a weak inhibitor of CYP3A4, CYP2C8, and CYP2D6 in vivo, but 
had no effect on CYP1A2, CYP2C9, or CYP2C19 [see Clinical Pharmacology 
(12.3) of full prescribing information]. Concomitant use of VOTRIENT with 
agents with narrow therapeutic windows that are metabolized by CYP3A4, 
CYP2D6, or CYP2C8 is not recommended. Coadministration may result in 
inhibition of the metabolism of these products and create the potential for 
serious adverse events. [See Clinical Pharmacology (12.3) of full prescribing 
information.] 7.3 Effect of Concomitant use of VOTRIENT and Simvastatin: 
Concomitant use of VOTRIENT and simvastatin increases the incidence of ALT 
elevations. Across monotherapy studies with VOTRIENT, ALT >3 X ULN was 
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Industry	Spotlight
New Medicare Code for Anemia Medication
In March 2012, Affymax and Takeda Pharmaceuticals ob-tained U.S. Food and Drug Ad-
ministration approval for Omontys 
(peginesatide) injection, a once-a-
month treatment for anemia in pa-
tients with chronic kidney disease 
(CKD) who are on dialysis. 
By mid-April, the Centers for 
Medicare & Medicaid Services (CMS) 
singled out the medication for a tem-
porary Q-code for federal reimburse-
ment, according to Affymax. CMS 
deemed the product important for all 
dialysis centers that are treating pa-
tients who receive Medicare-covered 
services. This new Q-code will go 
into effect on July 1, 2012.
The new Q-code provides dialy-
sis centers with an immediate reim-
bursement code so they can submit 
claims in a standardized manner and 
reduce the turnaround time for pay-
ment. “The designation of this Q-
code by CMS will help simplify their 
billing process for reimbursement 
when using this new once-monthly 
anemia treatment for CKD patients 
on dialysis,” said John Orwin, chief 
executive officer of Affymax. “The 
ability of dialysis centers to receive 
timely reimbursement for Omontys 
is important.”
According to CMS, the Q-code is 
used by CMS contractors when the 
existing, permanent national codes 
do not have an exact code for a prod-
uct or service covered by Medicare. 
By the end of the first quarter of 
2012 there were more than 200 Q-
codes in effect for all types of medi-
cal services.
The unique aspects of dialysis 
make its related treatments a fertile 
ground for Q-codes. Beginning Jan-
uary 1, 2010, Feraheme (ferumoxy-
tol), a different anemia medication, 
received two Q-codes for its use in 
patients—one code for patients with 
CKD, and the other code for patients 
with end stage renal disease. 
The entire Medicare coding sys-
tem, including the Q-codes and 
other specialized codes, is called 
the Healthcare Common Procedure 
Coding System (HCPCS) code set. 
If you have questions about HCPCS 
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reported in 126/895 (14%) of patients who did not use statins, compared with 
11/41 (27%) of patients who had concomitant use of simvastatin. If a patient 
receiving concomitant simvastatin develops ALT elevations, follow dosing 
guidelines for VOTRIENT or consider alternatives to VOTRIENT [see Warnings 
and Precautions (5.1)]. Alternatively, consider discontinuing simvastatin [see 
Warnings and Precautions (5.1)]. Insufficient data are available to assess the risk 
of concomitant administration of alternative statins and VOTRIENT.
8 USE IN SPECIFIC POPULATIONS 
8.1 Pregnancy: Pregnancy Category D [see Warnings and Precautions (5.10)]. 
VOTRIENT can cause fetal harm when administered to a pregnant woman. There 
are no adequate and well-controlled studies of VOTRIENT in pregnant women. In 
pre-clinical studies in rats and rabbits, pazopanib was teratogenic, embryotoxic, 
fetotoxic, and abortifacient. Administration of pazopanib to pregnant rats 
during organogenesis at a dose level of ≥3 mg/kg/day (approximately 0.1 
times the human clinical exposure based on AUC) resulted in teratogenic 
effects including cardiovascular malformations (retroesophageal subclavian 
artery, missing innominate artery, changes in the aortic arch) and incomplete 
or absent ossification. In addition, there was reduced fetal body weight, and 
pre- and post-implantation embryolethality in rats administered pazopanib at 
doses ≥3 mg/kg/day. In rabbits, maternal toxicity (reduced food consumption, 
increased post-implantation loss, and abortion) was observed at doses ≥30 mg/
kg/day (approximately 0.007 times the human clinical exposure). In addition, 
severe maternal body weight loss and 100% litter loss were observed at doses 
≥100 mg/kg/day (0.02 times the human clinical exposure), while fetal weight 
was reduced at doses ≥3 mg/kg/day (AUC not calculated). If this drug is used 
during pregnancy, or if the patient becomes pregnant while taking this drug, 
the patient should be apprised of the potential hazard to the fetus. Women of 
childbearing potential should be advised to avoid becoming pregnant while 
taking VOTRIENT. 8.3 Nursing Mothers: It is not known whether this drug 
is excreted in human milk. Because many drugs are excreted in human milk 
and because of the potential for serious adverse reactions in nursing infants 
from VOTRIENT, a decision should be made whether to discontinue nursing 
or to discontinue the drug, taking into account the importance of the drug to 
the mother. 8.4 Pediatric Use: The safety and effectiveness of VOTRIENT in 
pediatric patients have not been established. In repeat-dose toxicology studies 
in rats including 4-week, 13-week, and 26-week administration, toxicities in 
bone, teeth, and nail beds were observed at doses ≥3 mg/kg/day (approximately 
0.07 times the human clinical exposure based on AUC). Doses of 300 mg/
kg/day (approximately 0.8 times the human clinical exposure based on AUC) 
were not tolerated in 13- and 26-week studies with rats. Body weight loss and 
morbidity were observed at these doses. Hypertrophy of epiphyseal growth 
plates, nail abnormalities (including broken, overgrown, or absent nails) and 
tooth abnormalities in growing incisor teeth (including excessively long, brittle, 
broken and missing teeth, and dentine and enamel degeneration and thinning) 
were observed in rats at ≥30 mg/kg/day (approximately 0.35 times the human 
clinical exposure based on AUC) at 26 weeks, with the onset of tooth and nail 
bed alterations noted clinically after 4 to 6 weeks. 8.5 Geriatric Use: In clinical 
trials with VOTRIENT for the treatment of RCC, 196 subjects (33%) were  
aged ≥65 years, and 34 subjects (6%) were aged >75 years. No overall 
differences in safety or effectiveness of VOTRIENT were observed between 
these subjects and younger subjects. However, patients >60 years of age may 
be at greater risk for an ALT >3 X ULN. Other reported clinical experience has 
not identified differences in responses between elderly and younger patients, 
but greater sensitivity of some older individuals cannot be ruled out. 8.6 Hepatic 
Impairment: In clinical studies for VOTRIENT, patients with total bilirubin ≤1.5 
X ULN and AST and ALT ≤2 X ULN were included [see Warnings and Precautions 
(5.1)]. An analysis of data from a pharmacokinetic study of pazopanib in patients 
with varying degrees of hepatic dysfunction suggested that no dose adjustment 
is required in patients with mild hepatic impairment [either total bilirubin within 
normal limit (WNL) with ALT > ULN or bilirubin > 1 X to 1.5 X ULN regardless of 
the ALT value]. The maximum tolerated dose in patients with moderate hepatic 
impairment (total bilirubin >1.5 X to 3 X ULN regardless of the ALT value) was 
200 mg per day (N = 11). The median steady-state Cmax and AUC(0-24) achieved at 
this dose was approximately 40% and 29%, respectively of that seen in patients 
with normal hepatic function at the recommended daily dose of 800 mg.  
The maximum dose explored in patients with severe hepatic impairment  
(total bilirubin > 3 X ULN regardless of the ALT value) was 200 mg per day  
(N = 14). This dose was not well tolerated. Median exposures achieved at this 
dose were approximately 18% and 15% of those seen in patients with normal 
liver function at the recommended daily dose of 800 mg. Therefore, VOTRIENT 
is not recommended in these patients [see Clinical Pharmacology (12.3) of 
full prescribing information]. 8.7 Renal Impairment: Patients with renal cell 
cancer and mild/moderate renal impairment (creatinine clearance ≥30 mL/
min) were included in clinical studies for VOTRIENT. There are no clinical or 
pharmacokinetic data in patients with severe renal impairment or in patients 
undergoing peritoneal dialysis or hemodialysis. However, renal impairment 
is unlikely to significantly affect the pharmacokinetics of pazopanib since 
<4% of a radiolabeled oral dose was recovered in the urine. In a population 
pharmacokinetic analysis using 408 subjects with various cancers, creatinine 
clearance (30-150 mL/min) did not influence clearance of pazopanib. Therefore, 
renal impairment is not expected to influence pazopanib exposure, and dose 
adjustment is not necessary. 
10 OVERDOSAGE 
Pazopanib doses up to 2,000 mg have been evaluated in clinical trials.  
Dose-limiting toxicity (Grade 3 fatigue) and Grade 3 hypertension were each 
observed in 1 of 3 patients dosed at 2,000 mg daily and 1,000 mg daily, 
respectively. Treatment of overdose with VOTRIENT should consist of general 
supportive measures. There is no specific antidote for overdosage of VOTRIENT. 
Hemodialysis is not expected to enhance the elimination of VOTRIENT  
because pazopanib is not significantly renally excreted and is highly bound  
to plasma proteins.
13 NONCLINICAL TOXICOLOGY 
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenicity 
studies with pazopanib have not been conducted. However, in a 13-week study 
in mice, proliferative lesions in the liver including eosinophilic foci in 2 females 
and a single case of adenoma in another female was observed at doses of 1,000 
mg/kg/day (approximately 2.5 times the human clinical exposure based on AUC). 
Pazopanib did not induce mutations in the microbial mutagenesis (Ames) assay 
and was not clastogenic in both the in vitro cytogenetic assay using primary 
human lymphocytes and in the in vivo rat micronucleus assay. Pazopanib may 
impair fertility in humans. In female rats, reduced fertility including increased 
pre-implantation loss and early resorptions were noted at dosages ≥30 mg/kg/
day (approximately 0.4 times the human clinical exposure based on AUC). Total 
litter resorption was seen at 300 mg/kg/day (approximately 0.8 times the human 
clinical exposure based on AUC). Post-implantation loss, embryolethality, and 
decreased fetal body weight were noted in females administered doses ≥10 mg/
kg/day (approximately 0.3 times the human clinical exposure based on AUC). 
Decreased corpora lutea and increased cysts were noted in mice given ≥100 
mg/kg/day for 13 weeks and ovarian atrophy was noted in rats given ≥300 
mg/kg/day for 26 weeks (approximately 1.3 and 0.85 times the human clinical 
exposure based on AUC, respectively). Decreased corpora lutea was also noted 
in monkeys given 500 mg/kg/day for up to 34 weeks (approximately 0.4 times 
the human clinical exposure based on AUC). Pazopanib did not affect mating or 
fertility in male rats. However, there were reductions in sperm production rates 
and testicular sperm concentrations at doses ≥3 mg/kg/day, epididymal sperm 
concentrations at doses ≥30 mg/kg/day, and sperm motility at ≥100 mg/kg/
day following 15 weeks of dosing. Following 15 and 26 weeks of dosing, there 
were decreased testicular and epididymal weights at doses of ≥30 mg/kg/day 
(approximately 0.35 times the human clinical exposure based on AUC); atrophy 
and degeneration of the testes with aspermia, hypospermia and cribiform change 
in the epididymis was also observed at this dose in the 6-month toxicity studies 
in male rats.
17 PATIENT COUNSELING INFORMATION 
See Medication Guide. The Medication Guide is contained in a separate leaflet 
that accompanies the product. However, inform patients of the following:
•  Therapy with VOTRIENT may result in hepatobiliary laboratory abnormalities. 
Monitor serum liver tests (ALT, AST, and bilirubin) prior to initiation of 
VOTRIENT and at least once every 4 weeks for the first 4 months of treatment 
or as clinically indicated. Inform patients that they should report any of the 
following signs and symptoms of liver problems to their healthcare provider 
right away. 
 —yellowing of the skin or the whites of the eyes (jaundice), 
—unusual darkening of the urine, 
—unusual tiredness, 
—right upper stomach area pain.
•  Gastrointestinal adverse reactions such as diarrhea, nausea, and vomiting 
have been reported with VOTRIENT. Patients should be advised how to 
manage diarrhea and to notify their healthcare provider if moderate to severe 
diarrhea occurs.
•  Women of childbearing potential should be advised of the potential hazard to 
the fetus and to avoid becoming pregnant.
•  Patients should be advised to inform their healthcare providers of all 
concomitant medications, vitamins, or dietary and herbal supplements.
•  Patients should be advised that depigmentation of the hair or skin may occur 
during treatment with VOTRIENT.
•  Patients should be advised to take VOTRIENT without food (at least 1 hour 
before or 2 hours after a meal).
VOTRIENT is a registered trademark of GlaxoSmithKline.
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Have you considered sharing 
your experience in medical 
education research and help-
ing others learn about effec-
tive changes you have im-
plemented in your program? 
Consider submitting your ab-
stract to the Medical Educa-
tion Abstract category at the 
ASN Kidney Week 2012.
An important task for all physi-cians is to educate. This may ap-
ply to those teaching the next gen-
eration of nephrologists, but it also 
goes far beyond that task. Medical 
education includes information pro-
vided to patients, colleagues, nursing 
staff, dieticians, and trainees about 
concepts concerning physiology or 
pathophysiology. For example, teach-
ing a patient the reason to keep phos-
phorus levels controlled and not-
ing the improvement in subsequent 
laboratory results is an effective ed-
ucational intervention. In medical 
education research, the project must 
have a specific question with a meas-
urable outcome to determine the suc-
cess of the change. 
Although it might seem that medi-
cal education research is meant for 
academic institutions, this type of re-
search may be performed in all prac-
tice settings. The number of investi-
gations linking medical education and 
quality of care or patient outcomes is 
minimal (1). Research is needed to de-
termine whether the changes in medi-
cal education implemented are useful 
or wasted effort. An example is this 
could easily apply to fellowship train-
ing, where outcomes-based education 
has been implemented without strong 
evidence to back this change (2). Spe-
cifically, further investigation is neces-
sary to determine whether the type of 
education given to the next generation 
will create nephrologists who provide 
higher-quality care with improved 
patient outcomes. The following ex-
amples will highlight some potential 
areas of practice where medical educa-
tion research can be applied (Table 1).
Quality	improvement	projects
Quality improvement is a recertifica-
tion requirement for all nephrolo-
gists. This project could bring many 
members of a team together for col-
laboration on enhancing an educa-
tional aspect of practice (2). The Plan-
Do-Study-Act method is a model for 
testing a change that is implemented 
(3). The four steps guide the thinking 
process and lead to an outcome that is 
measured for success. 
Medical Education Research Can Improve the Future 
of Nephrology and Applies to All Types of Practice 





• Requirement for recertification
• Audience: trainees, nurses, dieticians, dialysis 
technologists, colleagues
• Teach concepts to help with patient compliance (laboratory 
review)
• Create a class to assist with the transition to dialysis 
(patient satisfaction survey)
Teaching at Work • Study how you deliver your message for efficacy
• Audience: trainees, nurses, dieticians, dialysis 
technologists, colleagues
• Learning at lunch: short nursing lectures (medical 
knowledge test)
• Create a video for dialysis patients (pretest and posttest)
• Supply handouts to improve medical knowledge (multiple 
methods)
Simulation • Requirement for credentialing organizations
• Audience: trainees, nurses, dieticians, dialysis 
technologists, colleagues
• Can be high-level or low-level technology
• Master procedure skills (direct observation)
• Practice patient interaction skills: delivering bad news, 
difficult patient (video observation)
Novel Ideas for 
Delivering Patient 
Care
• Test creative concepts 
• Audience: trainees, nurses, dieticians, dialysis 
technologists, colleagues
• Measure patient satisfaction after changing clinic structure 
(patient satisfaction survey)
• Assess exercise tolerance after starting a dialysis work out 
routine (interval analysis)
Qualitative	Measures Quantitative	Measures
Presurvey and postsurvey: opinion Presurvey and postsurvey: numerical
Patient satisfaction survey Medical knowledge test
Video observation Laboratory review
Interval analysis Patient outcomes






Sharing knowledge is a significant 
part of patient care delivery as well 
as trainee education. However, teach-
ing without measuring effectiveness 
does not answer whether the meth-
ods used to relay information are as 
good as they can be. Taking the time 
to frame a deficiency, pose an inter-
vention, and test the results over time 
can optimize best teaching practices. 
Simulation
Medical simulation is a rapidly grow-
ing field, and credentialing organiza-
tions are requiring it as part of the 
training curriculum. Simulation can 
be used to perfect technical skills in 
performing procedures but also to 
assist in improving interactions with 
patients. Whichever skill is being 
practiced, simulation provides an op-
portunity for feedback to be given to 
participants. Repeating these sessions 
can provide a way to evaluate learn-
ing over time (4).
Novel	ideas	for	delivering	care
Innovation can come in many forms. 
Examine teaching techniques or de-
livery of care methods that are new 
to the field. For example, increase 
the time you spend with patients by 
grouping those with similar medical 
problems together, such as monthly 
peritoneal dialysis visits. This gives 
patients a way to connect with oth-
ers in a similar situation, and it also 
allows teaching concepts of care only 
once to the group instead of repeat-
edly in separate patient visits. Assess 
whether this improves patients’ satis-
faction with their care, their medical 
knowledge, or ultimately their out-
comes.
Steps	to	educational	research
No matter the practice model, there 
are ways to implement educational 
research. Innovation and energy for 
a project are important, but without 
the tools to accomplish the task, no 
project will be successful. The proc-
ess of educational research should 
parallel the familiar scientific meth-
ods (5). 
Step 1: Formulate the question
The research question should be spe-
cific, with a measurable outcome. 
For example, you might notice that 
dialysis patients go through multi-
ple cannulations before starting their 
treatment. A research question could 
be this: Does staff education about 
cannulation improve successful nee-
dle placement rates?
Step 2: Measure the baseline
The measure used to determine suc-
cess should be assessed before the in-
tervention. This will validate that the 
perceived deficiency is truly present, 
and it will set the baseline for com-
parison after intervention. Deter-
mining the measure can be difficult. 
Traditional teaching has suggested 
quantitative findings to be the opti-
mal assessment: “The proof is in the 
numbers.” Educational research may 
focus on qualitative findings as a bet-
ter measure. Examples of measures 
can be found in Table 2.
Step 3: Plan the intervention
The intervention must be planned to 
address the specific topic. Keep the 
difficulty of material at the level of 
the audience. Use teaching methods 
that provide information in a variety 
of ways to target the largest audi-
ence. Some people learn by hearing 
(lectures), seeing (written word), or 
doing (simulation or workshops); 
therefore, it is wise to focus on inter-
ventions that address multiple means 
of knowledge delivery (6–8). 
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Log on to complete this activity at: 
www.tufts-hyponatremia.com
The goal of this activity is to improve the management of in-hospital hyponatremia by 
individual hospital specialists and to promote continuity of care among specialties.
Step 4: Implement the change
More is not always better. Focus 
on finding the most effective tool 
to deliver the information. It may 
take more than one session to have 
the learner retain the information. 
For example, it is advisable to give 
a lecture and then provide written 
language for review. Similarly, teach-
ing patients and having them teach it 
back is another effective method to 
get repetition and check understand-
ing.  
Step 5: Measure the 
intervention
Not all changes improve the out-
come; in fact, change might make it 
worse. Prove that the intervention is 
worth the extra effort, and make sure 
that the old way is not better. If the 
desired outcome is not met, reevalu-
ate the intervention and try again.
Step 6: Share your findings
Most importantly, unless all con-
cerned work together to share their 
successes and failures, progress in the 
field of nephrology education will 
be slow. Similar problems are seen 
in many practices, and if ideas for 
change can be shared with the com-
munity, improvement in the field 
will be enhanced (5). There has been 
a decline in the number of learn-
ers choosing nephrology as a career, 
which may be attributed to the style 
of presenting subject matter or to a 
lack of dedicated mentorship (9). 
Optimizing the delivery of curricu-
lum material to enhance understand-
ing might be one way we can lead 
more trainees to a career in the field.
An excellent avenue to share 
projects is through the ASN Kidney 
Week Educational Abstracts Cat-
egory. This category was developed 
in 2008 and is a place for sharing 
changes in educational programs that 
can make a difference in patients’ 
lives. These projects can be initiated 
and submitted by any part of the care 
team. Take time to consider adding a 
submission to the category this year. 
More information can be found at 
the ASN website. 
Laura Maursetter, DO, is a member of 
the ASN Workforce Committee and as-
sistant professor in the Division of Ne-
phrology at the University of Wisconsin 
Madison, where she serves as the associ-
ate program director.  She is a member 
of the ASN Workforce Committee that 
is focused on increasing interest in ne-
phrology as a career for trainees.
 
Mary K. Thompson is a PhD educa-
tor in the department of medicine at 
the University of Wisconsin-Madison. 
She works with fellowships across the 
department supporting education and 
curricular needs. 
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Hill Day 2012: ASN Leaders Put Kidney Disease in 
Legislative Spotlight 
The ASN Council, Public Policy Board, and Board of Advisors met with legislators on 
Capitol Hill as part of the biannual Board of Ad-
visors meeting on April 26, 2012. The second 
annual ASN Hill Day provided ASN leaders an 
opportunity to talk directly with lawmakers and 
House and Senate staff about issues of importance 
to ASN and the kidney care community. ASN 
leaders met with more than 50 congressional of-
fices, including more than a half-dozen meetings 
with senators and representatives themselves, and 
were divided into four teams to discuss one of the 
following issues: 
• National Institutes of Health (NIH) and Na-
tional Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK) funding and inves-
tigation of kidney health disparities, includ-
ing a bill (S.2163) recently introduced by Sen. 
Kent Conrad (D-ND) that promotes research 
regarding disparities and access to care.
• Support for legislation to extend lifetime cov-
erage of immunosuppressive drugs for kidney 
transplant recipients (S.1454/H.R.2969).
• ASN’s efforts to increase interaction between 
the nephrology community and the U.S. Food 
and Drug Administration (FDA).
• A complex set of issues and upcoming changes 
related to the Medicare end stage renal disease 
(ESRD) program and the practice of nephrol-
ogy.
ASN leaders met not only with senators and 
representatives from their home states and dis-
tricts, but also with key members of congressional 
committees with jurisdiction over the issues ASN 
discussed, either from an “authorizing” perspec-
tive (meaning that the committee can tell a cer-
tain program or agency what it is allowed to, or 
must, do) or from an “appropriations” perspective 
(meaning that the committee is in charge of de-
termining how much funding an agency or a pro-
gram receives).  
This Policy Update gives an in-depth description 
of the issues for ASN Hill Day 2012, and includes 
an article from members of the ASN Transplant 
Advisory Group that illustrates why advocating for 
legislation to extend lifetime coverage of immu-
nosuppressive drugs was—and continues to be—a 
top ASN policy priority.  
As noted above, ASN’s collaboration with the 
FDA is one of the society’s top policy priorities in 
2012. Several ASN leaders discussed this priority 
with members of Congress who oversee the FDA. 
Although ASN is still in the early stages of outlin-
ing this collaborative initiative with the FDA to 
protect kidney health, the society received positive 
feedback about its goals from members in both the 
House and Senate. Stay tuned to Kidney News for 
more details about this vitally important initiative 
in the coming months.   
ASN	Addresses	NIH	Research,	Health	
Disparities,	and	S.2163
During office meetings with House and Senate 
appropriators and other lawmakers, ASN leaders 
discussed the importance of supporting the NIH, 
which in turn supports innovative kidney disease 
research that will improve patient care, cut costs, 
and preserve the investigator pipeline. The bottom 
line—funding NIH is a smart investment because 
NIH research generates jobs, stimulates the econo-
my, and enables life-saving medical advancements. 
ASN leaders spoke about the public health im-
portance and economic benefits of kidney disease 
research. ASN supports the work of Congress to 
reduce the federal debt in a socially and fiscally re-
sponsible manner, which is why we urge continued 
investments in medical research. Publicly funded 
research supports one of every 500 full-time jobs 
in the United States, and every dollar invested 
in medical research generates $2.60 of economic 
activity. Furthermore, according to a 2010 study, 
research funding also generated 487,900 new jobs 
nationally and produced more than $68 billion in 
new economic activity in the United States.  
Most developed countries are dramatically in-
creasing their budgets for medical research. China 
in particular is ramping up investments in this 
arena. Currently, the United States is the world 
leader and can attract the best and brightest in-
vestigators from across the globe, but in order to 
maintain this position it is critical to protect medi-
cal research funding. Without this investment, the 
ability to sustain a pipeline of researchers from this 
country and abroad—and their future contribu-
tions to improving patient care and treatment and 
possible cures—will be lost.
Consequently, ASN leaders asked the House 
and Senate offices they met with for their support 
of $32 billion for the NIH and specifically $2.03 
billion for the NIDDK in the fiscal year 2013 
budget—the minimum investment necessary to 
avoid further loss of promising research and allow 
NIH’s and NIDDK’s budgets to keep pace with 
the rising cost of conducting biomedical research.
ASN leaders also explained the importance of 
health disparities research and requested support 
for the Kidney Disease Equitable Access, Prevention, 
and Research Act of 2012 (S.2163). Research has 
helped physicians understand some of the reasons 
why many minority populations are at higher risk 
for kidney disease, but without support for addi-
tional research we cannot move forward to address 
and resolve disparities in kidney care.  
Sen. Kent Conrad (D-ND) introduced S.2163 
to help resolve inequities in kidney disease health 
policy by addressing barriers to transportation, 
patient education, and access to insurance. For ex-
ample, S.2163 would provide key education for 
Medicare beneficiaries with stage V chronic kidney 
disease (CKD) through medical and clinical staff 
at dialysis facilities. Senate bill 2163 would also 
allow individuals with kidney failure to maintain 
their private insurance by extending the Medicare 
Secondary Payer period from 30 to 42 months af-
ter they quality for Medicare, which would achieve 
important savings for the Medicare program.
Leading up to Hill Day, ASN laid the ground-
work on the medical research advocacy front, 
including collaborating with the American So-
ciety of Pediatric Nephrology (ASPN) to send a 
letter supporting kidney disease research to both 
the House and Senate appropriations commit-
tees that was signed by numerous other members 
of the kidney community, representing patients, 
providers, and industry. ASN has received positive 
feedback regarding the letter, including a request 
from the office of Rep. Jeff Flake (R-AZ), who sits 
on the House Ways and Means Appropriations 
health subcommittee (which has significant influ-
ence over the NIH budget) to discuss kidney dis-
ease research and the NIDDK budget in particu-
lar. While this is a difficult time for Congress to 
make spending-related decisions, the importance 
of kidney disease research is squarely on the radar 
screens of those members with influence. 
ASN and ASPN are deeply grateful for the sup-
port of the Congressional Kidney Caucus, which 
submitted language for inclusion in the report 
the House Appropriations Committee submits to 
the full House of Representatives highlighting the 
importance of kidney disease research across the 
NIH and directed at patients of all ages. This re-
port is vitally important, as it explains to Congress 
the reasons for including the spending propos-
als in appropriations bills. In addition, ASN and 
ASPN worked with the caucus to include a specific 
funding recommendation of $2.03 billion for the 
NIDDK budget—the first time a specific budget 
level has been supported by the kidney commu-
nity.
ASN has taken a number of other steps such as:
• Joining more than 165 organizations in sending 
a letter urging Congress to support $32 billion 
in funding for NIH.
• Involving the ASN membership in a petition-
signing campaign urging the White House to 
support more funding for NIH.
• Joining more than 900 organizations in send-
ing a letter urging Congress to avert cuts to the 
overall Health and Human Services budget.
• Launching an ASN membership email cam-
paign to urge their members of Congress to 
By Grant Olan and Rachel Shaffer
support more research funding for NIH. Con-
tact your member at http://capwiz.com/asn/
home/.
ASN is grateful to the society’s leaders for helping 
make Hill Day 2012 a success, and the society will 
continue to engage lawmakers and their offices in 
the months to come as the budget process plays 
out and other pieces of legislation important to the 




Congress made a commitment to save the lives 
of people with kidney failure by establishing the 
Medicare ESRD program in 1972, a program that 
covers all citizens experiencing kidney failure, re-
gardless of age. This essential government program 
and the kidney professionals who implement it are 
at the forefront of the innovations, system trans-
formations, and pioneering changes that will affect 
other areas of health care. 
A key goal of ASN Hill Day was informing those 
lawmakers with oversight of the Medicare ESRD 
program, or those with a history of commitment 
to kidney disease and the Medicare ESRD pro-
gram, of the implications these profound reforms 
could have for patients and physicians. In order for 
ASN to achieve success in this area, it is crucial 
to gain the support of lawmakers who understand 
the complexity of these changes, who will support 
kidney professionals’ effort to enact change that 
focuses on improving care for a vulnerable popula-
tion, and who will allow time to assess efforts to 
reduce costs and measure the quality of care. 
ASN representatives discussed four key com-
ponents of the “evolving practice environment in 
nephrology.” 
First is the ongoing process of implementing the 
Medicare Improvements for Patients and Provid-
ers Act (MIPPA), including bundled payments for 
dialysis care. At the heart of ASN’s message was 
the principle that Congress should avoid future 
Medicare payment changes until recently enacted 
MIPPA changes are fully implemented. Meaning-
ful cost reductions will succeed only if patient care 
remains uncompromised. Evaluating the success of 
the program’s experience with bundled payment 
systems and pay-for-performance quality programs 
will serve as a model for needed changes to other 
areas of health care. 
Second, it is important for Congress to under-
stand the complexity of addressing the measures 
and programs related to improving the quality of 
health care. Because nephrology professionals pro-
vide care to a highly vulnerable patient population, 
achieving this goal requires consistent, evidence-
based evaluations of the quality of care provided. 
Promoting the use of the same measures across pro-
grams is crucial to facilitate consistent care, reduce 
unnecessary reporting burdens, and prevent costly 
data duplication. ASN is dedicated to helping de-
velop and ensure the consistency of quality metrics 
that fulfill these essential standards. 
Third, ASN discussed the society’s principles 
related to the potential development of integrated 
care delivery models. Foremost among these prin-
ciples (available in full at http://asn-online.org) is 
preservation of the patient-physician relationship. 
ASN’s advocates addressed the very real potential 
that such pilot or demonstration programs could 
pave the way to dramatic improvements in kidney 
care, but cautioned that establishing successful 
ones requires careful consideration of the potential 
effects on a vulnerable patient population. 
The fourth component of ASN’s message was the 
vital need to repeal the flawed sustainable growth 
rate and replace it with a sensible alternative. Ad-
dressing this fundamentally defective formula is 
key to ensuring that patients maintain access to 
care, and that physicians can count on the Medi-
care program to provide payments that accurately 
reflect the cost of care. 
Making	the	Case	for	Lifetime	
Immunosuppressive	Drug	Coverage
Advocating for legislation to extend lifetime coverage 
of immunosuppressive drugs (S.1454/H.R.2969) is a 
cornerstone of ASN’s public policy and Hill Day 2012 
messages. ASN leaders met with more than a dozen 
offices, specifically focusing on members of Congress 
who supported this bill when it was introduced in 
the 111th Congress, but who have not signed onto the 
bill in the 112th Congress (the current session). Here, 
members of the ASN Transplant Advisory Group Alan 
Leichtman, MD, David Cohen, MD, and Chair 
Michelle Josephson, MD, outline the history of this 
legislation and why it’s the right thing for Congress to 
do from every perspective, illustrating the many rea-
sons that this issue is at the top of ASN’s public policy 
priorities. 
Transplantation, for nearly all suitable trans-
plant candidates, is the preferable and most cost-
effective treatment for ESRD, and typically pro-
vides superior longevity, health, and quality of life 
when compared with dialysis. Median 5-year sur-
vival is nearly double for patients following renal 
transplantation compared with patients who re-
main on dialysis. For those patients with Medicare 
coverage from ESRD, Medicare will cover the costs 
of dialysis indefinitely but only the initial costs of a 
kidney transplant (1). For most transplant patients 
Medicare coverage ends after 36 months, leaving 
many patients unable to pay for the immunosup-
pressive medications required indefinitely to pre-
vent rejection. Consequently, financial hardship 
forces many to become non-adherent with their 
medical regimens—reducing their doses or discon-
tinuing their immunosuppressive medications en-
tirely. Financial hardship-related non-adherence in 
turn leads to rejection, transplant dysfunction with 
the associated costs of CKD, and the premature 
return to dialysis. Once patients return to dialy-
sis they are again covered by Medicare, at minimal 
estimated costs exceeding $82,000 annually com-
pared with approximately $11,000 to maintain a 
kidney transplant. It clearly makes neither clinical 
nor financial sense to pay indefinitely for the less 
efficacious and more expensive treatment, while 
denying long-term coverage for the more effective 
and less costly alternative. 
In addition there is a shortage of kidneys, and 
the deficit in the number of kidneys available for 
transplantation is exacerbated by the 15 percent of 
waitlisted patients seeking repeat transplantation. 
With lifetime immunosuppressive drug coverage, 
there is little doubt that many transplants would 
last longer, resulting in fewer patients returning to 
the waiting list for repeat transplantation, and thus 
more kidneys would be available for other trans-
plant candidates.
How widespread is this problem? While precise 
numbers are hard to come by, a survey conducted 
by the United Network for Organ Sharing and the 
American Society of Transplantation indicated that 
70 percent of kidney transplant programs reported 
that many of their patients had an extremely seri-
ous or very serious problem paying for their medi-
cations, and 68 percent reported deaths or graft 
losses attributable to cost-related immunosuppres-
sive medication non-adherence (2). While extend-
ing Medicare coverage for immunosuppressive 
medications will not entirely solve this problem, it 
would help a substantial number of these patients. 
Federal expenditures for kidney disease cur-
rently cost taxpayers more than $30 billion a year, 
about 6 percent of the Medicare budget. Expanded 
immunosuppressive medication coverage offers a 
more cost-effective way for the federal government 
to manage these expenses. For nearly 10 years the 
transplant community has lobbied Congress to ex-
tend coverage of immunosuppressive medications 
for kidney transplant recipients for the lifetime of 
the organ. A bill has been introduced in both the 
House and Senate to provide for this, and it has 
broad bipartisan support. The current lead spon-
sors are the physician Rep. Michael Burgess (R-
TX), Rep. Ron Kind (D-WI), Sen. Dick Durbin 
(D-IL), and Sen. Thad Cochran (R-MS). The cur-
rent House Ways and Means Committee Chairman 
Dave Camp (R-MI) was the lead sponsor for many 
years. ASN will continue to work with a coalition 
of transplant organizations to keep the patient im-
munosuppressive medication coverage extension 
bill at the top of many legislative priority lists. 
This current policy of paying for a kidney patient’s 
transplant but not providing the drugs necessary 
to keep the transplant and the patient alive defies 
common sense, is life threatening for patients, and 
costs the federal government untold millions in 
avoidable expenditures. When will common sense 
prevail?
Please visit the ASN’s Legislative Action Cent-
er (http://capwiz.com/asn/home) and send your 
members of Congress a message telling them how 
important this bill is for all patients with kidney 
disease. 
1. Gill JS, Tonelli M. Penny wise, pound foolish? 
Coverage limits on immunosuppression after 
kidney transplantation. N Engl J Med 2012; 
366:586–589. 
2. Evans RW, Applegate WH, Briscoe DM, et al. 
Cost-related immunosuppressive medication 
nonadherence among kidney transplant recipi-
ents. Clin J Am Soc Nephrol 2010; 5:2323–2328.
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Leader of ASN Grants Review  Committee Named 
Editor-in Chief of Kidney International; New Chair Named
After leading the American Society of Nephrology (ASN) Grants Pro-gram for 3 years, Detlef Schlon-
dorff, MD, has been named editor-in-chief 
of Kidney International. Under his guid-
ance, the ASN Grants Review Committee 
added two new opportunities for career 
development grants: the ASN–Association 
of Specialty Professors (ASP)–National 
Institute of Aging (NIA) Junior Develop-
ment Grant in Geriatric Nephrology, and 
the NephCure Foundation–ASN Research 
Grant. Schlondorff was also instrumental 
in expanding the ASN Student Scholar 
Grant Program and launching the new 
ASN Research Fellowship Program, which 
will fund its first 10 fellows later this year.
The ASN Grants Program distributes 
more than $3 million each year in research 
funding to medical students, fellows, new 
investigators, and established investigators. 
Last year ASN awarded a total of 31 re-
search grants.
“Dr. Schlondorff has been instrumen-
tal in maintaining the high caliber of 
quality of the ASN Grants Program, and 
expanding the program to reach more re-
searchers,” said ASN Past-President Joseph 
Bonventre, MD, PhD, FASN. “I am 
particularly impressed by his ability to 
manage an increasingly complex grants 
portfolio with increasing numbers of ap-
plications, and his leadership in strength-
ening ASN’s partnerships with the Halpin 
Foundation, the NephCure Foundation, 
ASP, and NIA.”
In addition to his success overseeing 
the ASN Grants Program, Schlondorff 
has a long list of academic and profes-
sional achievements. He currently serves 
as visiting professor of medicine at Mount 
Sinai School of Medicine, where he leads 
an active research laboratory. Schlon-
dorff has authored more than 300 peer-
reviewed original and review articles 
and book chapters, and has edited two 
textbooks. He is a member of numerous 
professional societies and has received the 
Franz Volhard Medal from the German 
Nephrology Society and the International 
Prize Luis Hernando from the Spanish 
Renal Foundation.
Schlondorff received his medical de-
gree at Ludwig Maximilians University 
in Munich, and continued his training 
in Germany and at the Albert Einstein 
ASN	Research	Grants
•		Career	Development	Grants	for	New	Investigators
•  Carl W. Gottschalk Research Scholar Grant (established in 1996)
•  John Merrill Grant in Transplantation (established in 2001)
•  The Halpin Foundation–ASN Research Grant (established in 2006)
•  Normal Siegel Research Scholar Grant (established in 2007)
•  The NephCure Foundation–ASN Research Grant (established in 2012)
• ASN-ASP-NIA Junior Development Grant in Geriatric Nephrology 
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College of Medicine and Montefiore 
Hospital in New York. He was professor 
of medicine and chief of the nephrology 
division at the Albert Einstein College of 
Medicine from 1988 to 1993, when he 
became chair and professor of medicine 
and director of the University Medical 
Policlinic Hospital Innenstadt of the Lud-
wig Maximillians University and eventu-
ally professor emeritus in 2007.
ASN is pleased to announce that Roy 
Zent, MD, PhD, will succeed Schlon-
dorff as chair of the ASN Grants Review 
Committee. Zent is professor of medicine 
at Vanderbilt University School of Medi-
cine and has served on the Grants Review 
Committee since 2008. “I am confident 
that Dr. Zent will provide excellent lead-
ership as ASN continues to expand and 
innovate its grants program,” said ASN 
President Ronald Falk, MD, FASN. 
“In particular, I’m excited that Dr. Zent 
agreed to help launch the ASN Research 
Fellowship Program this year.” 
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